Articles

2019

PLACEHOLDER TITLE
  1. Stemberger M, Gallenbach F, Schmit E, McEneny-King A, Germini F, Yeung CHT, Edginton AN, von Mackensen S, Kurnik K, Iorio A. Impact of Adopting Population Pharmacokinetics for Tailoring Prophylaxis in Haemophilia A Patients: A Historically Controlled Observational Study. Thromb Haemost. 2019 Mar;119(3):368-76.
  2. Eekels JJM, Althaus K, Bakchoul T, Kroll H, Kiefel V, Nazy I, Lee LS, Sachs UJ, Warkentin TE, Greinacher A. An international External Quality Assessment for laboratory diagnosis of Heparin‐Induced ThrombocytopeniaJ Thromb Haemost. 2019 Mar;17(3):525-31.
  3. Arnold DM, Jamula E, Heddle NM, Cook RJ, Hsia C, Sholzberg M, Lin Y, Kassis J, Blostein M, Larratt L, Amini S, Schipperus M, Carruthers J, Lane SJ, Li N, Kelton JG. Peri-Operative Eltrombopag or Immune Globulin for Patients with Immune Thrombocytopaenia (The Bridging ITP Trial): Methods and Rationale. Thomb Haemost. 2019 Mar;119(3):500-507.
  4. Heddle NM, Cook RJ, Liu Y, Zeller M, Barty RL, Acker JP, Eikelboom J, Arnold DM. The association between blood donor sex and age and transfusion recipient mortality: An exploratory analysis. Transfusion. 2019 Feb;59(2):482-91.
  5. Huyn A, Arnold DM, Kelton JG, Smith JW, Horsewood P, Clare R, Guarne A, Nazy I. Characterization of platelet factor 4 amino acids that bind pathogenic antibodies in heparin-induced thrombocytopenia. J Thromb Haemost. 2019 Feb;17(2):389-399.
  6. Warkentin TE. Microvascular Thrombosis and Ischaemic Limb Losses in Critically Ill Patients. Hamostaseologie. 2019 Feb;39(1):6-19.
  7. Iba T, Levy JH, Wada H, Thachil J, Warkentin TE, Levi M, Subcommittee on Disseminated Intravascular Coagulation. Differential diagnoses for sepsis-induced disseminated intravascular coagulation: communication from the SSC of the ISTH. J Thromb Haemost. 2019 Feb;17(2):415-419.
  8. Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, Noone D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther MA, Iorio A. Test-retest properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire and its constituent domains. Haemophilia. 2019 Jan;25(1):75- 83.
  9. Mette Kjaer, Gerald Bertrand, Tamam Bakchoul, Edwin Massey, Jillian M. Baker, Lani Lieberman, Susano Tanael, Andreas Greinacher, Michael F. Murphy, Donald M. Arnold, Shoma Baidya, James Bussel, Heather Hume, Cécile Kaplan, Dick Oepkes, Greg Ryan, Helen Savoia, Nadine Shehata, Jens Kjeldsen‐Kragh, on behalf of International Collaboration for Transfusion Medicine Guidelines. Maternal HPA‐1a antibody level and its role in predicting the severity of Fetal/Neonatal Alloimmune Thrombocytopenia: a systematic review. Vox. 2019;114:79-94.

E-publications:

  1. Lani Lieberman, Andreas Greinacher, Michael F. Murphy, James Bussel, Tamam Bakchoul, Stacy Corke, Mette Kjaer, Jens Kjeldsen-Kragh, Gerald Bertrand, Dick Oepkes, Jillian M. Baker, Heather Hume, Edwin Massey, Cécile Kaplan, Donald M. Arnold, Shoma Baidya, Greg Ryan, Helen Savoia, Denise Landry, Nadine Shehata for the International Collaboration for Transfusion Medicine Guidelines (ICTMG). Fetal and Neonatal Alloimmune Thrombocytopenia: Recommendations for Evidence-Based Practice, An International Approach. British Journal of Haematology. 2019 Mar 3.
  2. Vrbensky JR, Moore JE, Arnold DM, Smith JW, Kelton JG, Nazy I. The Sensitivity and Specificity of Platelet Autoantibody Testing in Immune Thrombocytopenia: A Systematic Review and Meta- Analysis of a Diagnostic Test. J Thromb Haemost. 2019 Feb 23. 
  3. Fiorellino J, Elahie AL, Warkentin TE. Acute haemolysis, DIC and renal failure after transfusion of uncross‐matched blood during trauma resuscitation: illustrative case and literature reviewTransfusion Medicine. 2018 Feb 19.
  4. Bussel JB, Arnold DM, Boxer MA, Cooper N, Mayer J, Zayed H, Tong S, Duliege AM. Long- Term Fostamatinib Treatment of Adults with Immune Thrombocytopenia (ITP) during the Phase 3 Clinical Trial Program. Am J Hematol. 2019 Feb 19. 
  5. Ivetic N, Arnold DM, Smith JW, Huynh A, Kelton JG, Nazy I. A platelet viability assay (PVA) for the diagnosis of heparin-induced thrombocytopenia. Platelets. 2019 Jan: 1-5.

2018

PLACEHOLDER TITLE
  1. Shih AW, Liu A, Elsharawi R, Crowther MA, Cook RJ, Heddle NM. Systematic reviews of guidelines and studies for single versus multiple unit transfusion strategies. Transfusion. 2018 Dec;58(12):2841-60.
  2. Petermann R, Bakchoul T, Curtis BR, Mullier F, Miyata S, Arnold DM, Subcommittee on Platelet Immunology. Investigations for fetal and neonatal alloimmune thrombocytopenia: communication from the SSC of the ISTH. J Thromb Haemost. 2018 Dec:16(12):2526-2529.
  3. Balitsky AK, Kelton JG, Arnold DM. Managing antithrombotic therapy in immune thrombocytopenia: development of the TH2 risk assessment score. Blood. 2018 Dec 20;132(25):2684-86.
  4. Makris M, Iorio A. Prehospital fresh frozen plasma: Universal life saver or treatment in search of a target population?. Res Pract Thromb Haemost. 2018 Dec 12;3(1):12-14.
  5. Warkentin TE. Natural, not immune; classical, not alternative. Blood. 2018 Dec 6;132(23):2421-2.
  6. Kelton JG, Vrbenski JR, Arnold DM. How do we diagnose immune thrombocytopenia in 2018? Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):561-567.
  7. Cuker A, Arepally GM, Chong BH, Cines DB, Greinacher A, Gruel Y, Linkins LA, Rodner SB, Selleng S, Warkentin TE, Wex A, Mustafa RA, Morgan RL, Santesso N. American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia. Blood Adv. 2018 Nov 27; 22 (2): 3360-3392.
  8. Warkentin TE. HIT-associated thrombosis: from arterial to venous to venous limb gangrene. J Thromb Haemost. 2018 Nov; 16 (11): 2128-2132.
  9. Vrbensky JR, Nazy I, Toltl LJ, Ross C, Ivetic N, Smith JW, Kelton JG, Arnold DM. Megakaryocyte apoptosis in immune thrombocytopenia. Platelets. 2018 Nov;29(7):729-32.
  10. MacIsaac J, Siddiqi R, Jamula E, Li N, Baker S, Webert KE, Evanovich D, Heddle NM, Arnold DM. Systematic review of Rituximab for autoimmune diseases: A potential alternative to intravenous immune globulin.  Transfusion. 2018 Nov;58(11):2729-35.
  11. Warkentin TE, Morin PA, Heddle NM. Neutropenia and monocytopenia in recurrent anaphylactoid reactions after red blood cell transfusions in a woman with immunoglobulin A (IgA) deficiency and anti-IgA. Transfusion. 2018 Oct;58(10):2320-25.
  12. McEneny-King A, Chelle P, Iorio A, Edginton AN. The effect of unmeasurable endogenous plasma factor activity levels on factor VIII dosing in patients with severe hemophilia A. Thromb Res. 2018 Oct;170:53-59. 
  13. Rozmus J, Ivison S, Kariminia A, Leung VM, Sung S, Subrt P, Lee SJ, Boilard E, Walker I, Foley R, Lipton J, Gallagher G, Couban S, Schultz KR. Higher levels of free plasma mitochondrial DNA are associated with the onset of chronic GvHD. Bone Marrow Transplant. 2018 Oct;53(10):1263-9.
  14. Warkentin TE, Sheppard JI, Dinkins LA, Arnold DM, Nazy I. High sensitivity and specificity of an automated IgG-specific chemiluminescence immunoassay for diagnosis of HIT. Blood. 2018 Sep 20;132(12):1345-9.
  15. Nossair F, Schoettler P, Starr J, Chan AKC, Kirov I, Paes B, Mahajerin A. Pediatric superior vena cava syndrome: An evidence‐based systematic review of the literaturePediatric Blood and Cancer. 2018 Sept;65(9):e27225
  16. Douketis JD, Spyropoulos AC, Anderson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Gal GL, Templier GL, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. Erratum to: The Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) Study for Patients on a Direct Oral Anticoagulant who Need an Elective Surgery or Procedure: Design and Rationale. Thromb Haemost. 2018 Sep;118(9):1679-80.
  17. Gantioqui J, Stevic I, Atkinson H, Chan AKC. Rivaroxaban and dabigatran did not affect clotting profiles in plasma reconstituted with varying levels of autologous platelets to the same degree as heparin when evaluated using thromboelastography. Blood Coagul Fibrinolysis. 2018 Sep;29(6):521-7.
  18. Mannucci PM, Nobil A, Marchesini E, Oliovecchio E, Cortesi L, Coppola A, Santagostino E, Radossi P, Castaman G, Valdre L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Peyvandi F, Iorio A. Rate and appropriateness of polypharmacy in older patients with hemophilia compared with age-matched controls. Haemophilia. 2018 Sept; 24 (5): 726-732.
  19. Nero J, Araneta P, Warkentin T, Moodley O. Severe autoimmune LMWH-induced thrombocytopenia presenting with aortic thromboses, adrenal hemorrhage and pulmonary embolism: response to high-dose intravenous immunoglobulin. Cdn J Gen Intern Med. 2018 Aug 27; 13 (3): 29-34.
  20. Linkins LA, Hu G, Warkentin TE. Systematic review of fondaparinux for heparin-induced thrombocytopenia: When there are no randomized controlled trials. Res Pract Thromb Haemost. 2018 Aug 9;2(4):678-83.
  21. Chai-Adisaksopha C, Skinner MW, Curtis R, Frick N, Nichol MB, No-one D, O'Mahony B, Page D, Stonebraker J, Thabane L, Crowther M, Iorio A. Psychometric properties of the Patient Reported Outcomes, Burdens and Experiences (PROBE) questionnaire. BMJ Open. 2018 Aug 8;8(8):e021900.
  22. Kavsak PA, Ainsworth C, Arnold DM, Scott T, Clark L, Ivica J, Mackett K, Whitlock R, Worster A. The potential role of a turbidimetric heart-type fatty acid-binding protein assay to aid in the interpretation of persistently elevated, non-changing, cardiac troponin I concentrations. Clin Biochem. 2018 Aug;58:53-9.
  23. Legault K, Schunemann H, Hillis C, Yeung C, Akl EA, Carrier M, Cervera R, Crowther M, Dentali F, Erkan D, Espinosa G, Khamashta M, Meerpohl JJ, Moffat K, O'Brien S, Pengo V, Rand JH, Rodriguez Pinto I, Thom L, Iorio A. McMaster RARE-Bestpractices clinical practice guideline on diagnosis and management of the catastrophic antiphospholipid syndrome. J Thromb Haemost. 2018 Aug; 16(8): 1656-1664.
  24. Qadri SM, Eltringham-Smith LJ, Bhakta V, Sheffield WP. Thromboelastometry reveals similar hemostatic properties of purified fibrinogen and a mixture of purified cryoprecipitate protein components.. Clin Chem Lab Med. 2018 Jul 26;56(8):e210-13.
  25. Dao E, Zeller MP, Wainman BC, Farquharson MJ. Feasibility of the use of a handheld XRF analyzer to measure skin iron to monitor iron levels in critical organs. Journal of Trace Elements in Medicine and Biology. July 2018;50:305-11.
  26. Ragni MV, Croteau SE, Morfini M, Cnossen MH, Iorio A, Subcommittee on Factor VIII, Factor IX, and Rare Bleeding Disorders. Pharmacokinetics and the transition to extended half-life factor concentrates: communication from the SSC of the ISTH. J Thromb Haemost. 2018 Jul;16(7):1437-41.
  27. Pavenski K, Stanworth S, Fung M, Wood EM, Pink J, Murphy MF, Hume H, Nahirniak S, Webert KE, Tanael S, Landry D, Shehata N; for the International Collaboration for Transfusion Medicine Guidelines (ICTMG). Quality of Evidence-Based Guidelines for Transfusion of Red Blood Cells and Plasma: A Systematic Review. Transfusion Medicine Reviews. 2018 July, 32 (3), 135-143.
  28. Pieter F. van der Meer, Paula F. Ypma, Nan van Geloven, Joost A. van Hilten, Rinie J. van Wordragen-Vlaswinkel, Okke Eissen, Jaap J. Zwaginga, MIchael Trus, Erik A.M. Beckers, Peter te Boekhorst, Alan Tinmouth, Yulia Lin, Cyrus Hsia, David Lee, Philip J. Norris, Raymond P. Goodrich, Anneke Brand, Tor Hervig, Nancy M. Heddle, Johanna G. van der Bom, and Jean-Louis H. Kerkhoffs. Hemostatic efficacy of pathogen-inactivated- versus untreated- platelets: a randomized controlled trialBlood. 2018 Jul 12;132(2):223-31.
  29. Duan A, Jackson Chornenki NL, Hillis CM, Gupta V, Anand SS, Siegal Dm, Leong DP. Antiplatelet use in patients with essential thrombocythemia: A survey of opinion and Canadian practiceThromb Res. 2018 May 3;167:6-8.
  30. Bussel J, Arnold DM, Grossbard E, Mayer J, Trelinski J, Homenda W, Hellmann A, Windyga J, Sivcheva L, Khalafallah AA, Zaja F, Cooper N, Markovstov V, Zayed H, Duliege AM. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: Results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018 Jul;93(7):921-30.
  31. Wong PPC, Kariminia A, Jones D, Eaves CJ, Foley R, Ivison S, Couban S, Schultz KR. Plerixafor effectively mobilizes CD56bright NK cells in blood providing an allograft predicted to protect against GvHD. Blood. 2018 Jun 21;131(25):2863-6.
  32. Warkentin TE, Arnold DM, Kelton JG, Sheppard JI, Smith JW, Nazy I. Platelet-activating antibodies are detectable at the earliest onset of heparin-induced thrombocytopenia, with implications for the operating characteristics of the serotonin-release assay. Chest. 2018 Jun;153(6):1396-404. 
  33. Pai M, Adhikari NKJ, Ostermann M, Heels-Ansdell D, Douketis JD, Skrobik Y, Qushmag I, Meade M, Guyatt G, Geerts W, Walsh MW, Crowther MA, Friedrich JO, Blurry L, Bellomo R, Brandao da Silva N, Costa Filho R, Cox MJ, Alves Silva S, Cook DJ, PROTECT (Prophylaxis for Thromboembolism in Critical Care Trial) Investigators. Low-molecular-weight heparin venous thromboprophylaxis in critically ill patients with renal dysfunction: A subgroup analysis of the PROTECT trial. PLOS One. 2018 Jun 1;13(6):e0198285. 
  34. Feldman B, Rivard GE, Babyn P, Wu JKM, Steele M, Poon M, Card RT, Israels SJ, Laferriere N, Gill K, Chan AK, Carcao M, Klaassen RJ, Cloutier S, Price VE, Dover S, Blanchette VS. Tailored frequency-escalated primary prophylaxis for severe haemophilia A: results of the 16-year Canadian Hemophilia Prophylaxis Study longitudinal cohort. The Lancet Haematology. 2018 Jun;5(6):e252-60.
  35. Langlois GP, Arnold DM, Potts J, Leber B, Dale DC, Mackey MC. Cyclic thrombocytopenia with statistically significant neutrophil oscillations. Clinical Case Reports. 2018 May 31;6(7):1347-52.
  36. Iorio A, Edginton AN, Blachette V, Blatny J, Boban A, Cnossen M, Collins P, Croteau SE, Fischer K, Hart DP, Ito S, Korth-Bradley J, Lethagen S, Lillicrap D, Makris M, Mathot R, Morfini M, Neufeld EJ, Spears J. Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations. Research and Practice in Thrombosis and Haemostasis. 2018 May 20;1-14.
  37. Warkentin TE, Climans TH, Morin PA. Intravenous Immune Globulin to Prevent Heparin-Induced Thrombocytopenia. N Engl J Med. 2018 May 10;378(19):1845-8.
  38. Nazy I, Clare R, Staibano P, Warkentin TE, Larche M, Moore JC, Smith JW, Whitlock RP, Kelton JG, Donald DM. Cellular immune responses to platelet factor 4 and heparin complexes in patients with heparin‐induced thrombocytopenia. Journal of Thrombosis and Haemostasis. 2018 May 3;16:1-11.
  39. Qadri SM, Donkor DA, Nazy I, Branch DR, Sheffield WP. Bacterial neuraminidase-mediated erythrocyte desialylation provokes cell surface aminophospholipid exposure. Eur J Haematol. 2018 May;100(5):502-10.
  40. Athale UH, Mizrahi T, Laverdiere C, Nayiager T, Delva Y-L, Foster G, Thabane L, David M, Leclerc J-M, Chan AKC. Impact of baseline clinical and laboratory features on the risk of thrombosis in children with acute lymphoblastic leukemia: A prospective evaluation. Pediatric Blood and Cancer. 2018 May;65(5):e26938.
  41. Huynh A, Arnold DM, Moore JC, Smith JW, Kelton JG, Nazy I. Development of high-yield expression and purification system for platelet factor 4. Platelets. 2018 May;29(3):249-56.
  42. Croteau SE, Callaghan MU, Davis J, Dunn AL, Guerrera M, Khan O, Neufeld EJ, Raffini LJ, Recht M, Wang M, Iorio A. Focusing in on use of pharmacokinetic profiles in routine hemophilia care. Res Pract Thromb Haemost. 2018 May 27;2(3):607-614.
  43. Pierce GF, Iorio A. Past, present and future of haemophilia gene therapy: From vectors and transgenes to known and unknown outcomes. Haemophilia. 2018 May;24 Suppl 6: 60-7.
  44. Tan JH, Mohamad Y, Tan CLH, Kassim M, Warkentin TE. Concurrence of symmetrical peripheral gangrene and venous limb gangrene following polytrauma: a case report. J Med Case Rep. 2018 May 19;12(1):131.
  45. Strike K, Uy M, Lawson W, Squire S, Iorio A, Stein N, Jackson S, Chan A. Point‐of‐care ultrasonography in haemophilia care: Training and competency for muscular haematomas. Haemophilia. 2018 May; 24(3): 335-337.
  46. Karkouti K, Callum J, Rao V, Heddle N, Farkouh ME, Crowther MA, Scales DC. Protocol for a phase III, non-inferiority, randomised comparison of a new fibrinogen concentrate versus cryoprecipitate for treating acquired hypofibrinogenaemia in bleeding cardiac surgical patients: the FIBRES trial. BMJ Open. 2018 Apr 20;8(4):e020741.
  47. Sheffield WP, Eltringham-Smith LJ, Bhakta V. A factor XIa-activatable hirudin-albumin fusion protein reduces thrombosis in mice without promoting blood loss. BMC Biotechnol. 2018 Apr 5;18(1):21.
  48. Iorio A, Skinner MW, Clearfield E, Messner D, Pierce GF, Witkop M, Tunis S; for the coreHEM panel. Core outcome set for gene therapy in haemophilia: Results of the coreHEM multistakeholder project. Haemophilia. 2018 Apr 2;00:1-6.
  49. Chai-Adisaksopha C, Iorio A, Crowther MA, de Miguel J, Salgado E, Zdraveska M, Fernández-Capitán C, Nieto JA, Barillari G, Bertoletti L, Monreal M; RIETE investigators. Vitamin K Antagonists after 6 Months of Low-Molecular-Weight Heparin in Cancer Patients with Venous Thromboembolism. Am J Med. 2018 Apr;131(4):430-7.  
  50. Nazy I, Kelton JG, Moore JC, Clare R, Horsewood P, Smith JW, Ivetic N, D'Souza V, Li N, Arnold DM. Autoantibodies to Thrombopoietin and the Thrombopoietin Receptor in Patients with Immune Thrombocytopenia. Autoantibodies to Thrombopoietin and the Thrombopoietin Receptor in Patients with Immune Thrombocytopenia. British Journal of Hematology. 2018 Apr;181(2):234-41.  
  51. Lai AT, Zeller MP, Millen T, Kavasak P, Szczeklik W, Elahie A, Alhazzani W, D'Aragon F, Jaeschke R, Lamontagne F, Karachi T, Cook D, Meade M, Rockwerg B; Canadian Critical Care Trials Group. Chloride and Other Electrolyte Concentrations in Commonly Available 5% Albumin Products. Crit Care Med. 2018 Apr;46(4):e326-9. 
  52. Shih AW, Lam AS, Warkentin TE. Levofloxacin-Induced Acute Immune-Mediated Thrombocytopenia of Rapid-Onset. J Pharm Pract. 2018 Apr;31(2):234-7.   
  53. Cushing MM, Kelley J, Klapper E, Friedman DF, Goel R, Heddle NM, Hopkins CK, Karp JK, Pagano MB, Perumbeti A, Ramsey G, Roback JD, Schwartz J, Shaz BH, Spinella PC, Cohn CS. Critical developments of 2017: a review of the literature from selected topics in transfusion. A committee report from the AABB Clinical Transfusion Medicine Committee. Transfusion. 2018 Apr;58(4):1065-75. 
  54. Qadri SM, Donkor DA, Yan M, Nig S, Branch DR, Seghatchian J, Sheffield WP. Red blood cells, still vital after all these years: Commentary on Canadian Blood Services' International Symposium 2017. Transfusion and Apheresis Science. 2018 Apr;57(2):298-303.
  55. Shih AW, Diep C, Jamula E, Heddle NM, Parvizian M, Hillis CM. Impact of organizational interventions on reducing inappropriate intravenous immunoglobulin (IVIG) usage: a systematic review and meta-analysis. Transfusion and Apheresis Science. 2018 Apr;57(2):215-21.
  56. Dyer C, Alquist CR, Cole-Sinclair M, Curnow E, Dunbar NM, Estcourt LJ, Kaufman R, Kutner JM, McCullough J, McQuilten Z, Potiphar L, Rioux-Masse B, Slichter S, Tinmouth A, Webert K, Yokoyama AP, Stanworth SJ; BEST Collaborative. A multicentred study to validate a consensus bleeding assessment tool developed by the biomedical excellence for safer transfusion collaborative for use in patients with haematological malignancy. Vox San, 2018 Apr;113(3):251-9.
  57. Chaturvedi S, Arnold DM, McCrae KR. Splenectomy for Immune Thrombocytopenia: down but not out. Blood. 2018 Mar 15;131(11):1172-82.
  58. Nazy I, Cuker A. Statins for high cholesterol ... and for low platelets? Blood. 2018 Mar 15;131(11):1159-61.
  59. Crowther MA, Lim W. Resolving Concerns With the Newer Oral Anticoagulant Medications: Is Hepatotoxicity a Real Concern?. J Am Coll Cardiol. 2018 Mar 13;71(10):1114-6.
  60. Warkentin TE. Symmetrical Peripheral Gangrene: Mechanisms for Limb Loss in the ICU in Patients With Retained Pulses. Clinical Pulmonary Medicine. 2018 Mar;25(2):61-6.
  61. Liesner RJ, Abashidze M, Aleinikova O, Altisent C, Belletrutti MJ, Borel-Derlon A, Carcao M, Chambost H, Chan AKC, Dubey L, Ducore J, Fouzia NA, Gattens M, Gruel Y, Buillet B, Kavardakova N, El Khorassani M, Klukowska A, Lambert T, Lohade S, Sigaud M, Turea V, Wu JKM, Vdovin V, Pavlova A, Jansen M, Belyanskaya L, Walter O, Knaub S, Neufeld EJ. Immunogenicity, efficacy and safety of Nuwiq® (Human- cl rhFVIII) in previously untreated patients with severe haemophilia A - Interim results from the NuProtect study. Haemophilia. 2018 Mar;24(2):211-20.
  62. Lucier, K., Movilla, R., Parvizian, M., Siddiqui, R., Gabriele, E., Bourque, M., MacIsaac, J., Moorehead, P., Chan, A., Heddle, N., Lane, S.J. A brief survey of clinicians' perceptions of parent preferences for involvement in obstetrical and perinatal management decisions in hemophilia. Haemophilia. 2018 Mar;24(2):e80-83.
  63. Skinner MW, Chai-Adisaksopha C, Curtis R, Frick N, Nichol M, Noone D, O'Mahony B, Page D, Stonebraker JS, Iorio A. The Patient Reported Outcomes, Burdens and Experiences (PROBE) Project: development and evaluation of a questionnaire assessing patient reported outcomes in people with haemophilia. BMC. 2018 Feb 27;4:58.
  64. Marchesini E, Oliovecchio E, Coppola A, Santagostino E, Radossi P, Castaman G, Valdrè L, Santoro C, Tagliaferri A, Ettorre C, Zanon E, Barillari G, Cantori I, Caimi TM, Sottilotta G, Iorio A, Mannucci PM. Comorbidities in persons with haemophilia aged 60 years or more compared with age-matched people from the general population. Haemophilia. 2018 Jan;24(1):e6-10.
  65. Tullius BP, Athale U, van Ommen CH, Chan AKC, Palumbo JS, Balagtas JMS, for the Subcommittee on Hemostasis and Malignancy and the Submcommittee on Pediatric/Neonatal Thrombosis and Hemostasis. The identification of at-risk patients and prevention of venous thromboembolism in pediatric cancer: Guidance form the SSC of the ISTH. Journal of Thrombosis and Haemstasis. 2018 Jan;16(1):175-80.
  66. Piran S, Schulman S, Panju M, Pai M. Oral anticoagulant dosing, administration, and storage: a cross-sectional survey of Canadian health care providers. J Thromb Thrombolysis. 2018 Jan;45(1):180-5.
  67. Zeller MP, Barty R, Dunbar NM, Elahie A, Flanagan P, Garritsen H, Kutner JM, Pagano MB, Poglod R, Rogers TS, Staves J, van Wordragen-Vlaswinkel M, Zwaginga JJ, Murphy MF, Heddle NM, Yazer MH, BEST Collaborative. An international investigation into AB plasma administration in hospitals: how many AB plasma units were infused? The HABSWIN study. Transfusion. 2018 Jan;58(1):151-7.
  68. Ning S, Heddle NM, Acker JP. Exploring donor and product factors and their impact on red cell post-transfusion outcomes. Transfusion Med Rev. 2018 Jan;32(1):28-35.
  69. Sheffield W, P, Eltringham-Smith L, J, Bhakta V. Fusion to Human Serum Albumin Extends the Circulatory Half-Life and Duration of Antithrombotic Action of the Kunitz Protease Inhibitor Domain of Protease Nexin 2. Cell Physiol Biochem. 2018;45:772-782. 

2017

PLACEHOLDER TITLE
  1. Iorio A. Using pharmacokinetics to individualize hemophilia therapy. Hematology: Am Soc Hematol Educ Program. Hematology. 2017 Dec 8;2017(1):595-604.
  2. Douketis JD, Spyropoulos AC, Andreson JM, Arnold DM, Bates SM, Blostein M, Carrier M, Caprini JA, Clark NP, Coppens M, Dentali F, Duncan J, Gross PL, Kassis J, Kowalski S, Lee AY, Le Gal G, Le Templier G, Li N, MacKay E, Shah V, Shivakumar S, Solymoss S, Spencer FA, Syed S, Tafur AJ, Vanassche T, Thiele T, Wu C, Yeo E, Schulman S. The perioperative anticoagulant use for surgery evaluation (PAUSE) study for patients on a direct oral anticoagulant who need an elective surgery or procedure: Design and Rationale. Thromb Haemost. 2017 Dec;117(12):2415-24.
  3. Iorio A, Blanchette V, Blatny J, Collins P, Fischer K, Neufeld E. Estimating and interpreting the pharmacokinetic profiles of individual patients with haemophilia A or B using a population pharmacokinetic approach: communication from the SSC of the ISTH. J Thromb Haemost. 2017 Dec;15(12):2461-5.
  4. Ghanem KM, Dhayni R, Al-Aridi C, Tarek N, Tamim H, Chan AKC, Saab R, Abboud M, El-Solh H, Muwakkit SA. Cerebral sinus venous thrombosis during childhood acute lymphoblastic leukemia therapy: Risk factors and management. Pediatric Blood and Cancer. 2017 Dec;64(12).
  5. Chai-Adisaksopha C, Iorio A, Hillis C, Siegal D, Witt DM, Schulman S, Crowther M. Warfarin resumption following anticoagulant-associated intracranial hemorrhage: A systematic review and meta-analysis. Thromb Res. 2017 Dec;160:97-104.  
  6. Arnold DM, Nazy I, Clare R, Jaffer AM, Aubie B, Li N, Kelton JG. Misdiagnosis of primary immune thrombocytopenia and frequency of bleeding: lessons from the McMaster ITP Registry. Blood Adv. 2017 Nov 28;1(25):2414-20.
  7. Agarwal A, Firdouse M, Brar N, Yang A, Lambiris P, Chan AK, Mondal TK. Incidence and Management of Thrombotic and Thromboembolic Complications Following the Norwood Procedure: A Systematic Review. Clinical and Applied Thrombosis/Hemostasis. 2017 Nov;23(8):911-21. 
  8. Warkentin TE. Fondaparinux for treatment of heparin-induced thrombocytopenia: too good to be true? J Am Coll Cardiol. 2017 Nov 28;70(21):2649-2651. [Editorial commentary on: Schindewolf M, Steindl J, Beyer-Westendorf J, Schellong S, Dohmen PM, Brachmann J, Madlener K, Pötzsch B, Klamroth R, Hankowitz J, Banik N, Eberle S, Müller MM, Kropff S, Lindhoff-Last E. Use of fondaparinux off-label or approved anticoagulants for management of heparin-induced thrombocytopenia. J Am Coll Cardiol. 2017 Nov 28;70(21):2636-48.
  9. Greinacher A, Selleng K, Warkentin TE. Autoimmune heparin-induced thrombocytopenia. J Thromb Haemost. 2017 Nov;15(11):2099-114.
  10. Branchford BR, Mahajerin A, Raffini L, Chalmers E, van Ommen CH, Chan AKC, Goldenberg NA, and for the Subcommittee on Pediatric/Neonatal Hemostais and Thrombosis. Recommendations for standardized risk factor definitions in pediatric hospital-acquired venous thromboembolism to inform future prention trials: Communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2017 Nov;15(11):2274-8.
  11. Cook RJ, Heddle NM, Lee KA, Arnold DM, Crowther MA, Devereaux PJ, Ellis M, Figueroa P, Furz A, Roxby D, Sessler DI, Sharon Y, Sobieraj-Teague M, Warkentin TE, Webert KE, Barty R, Liu Y, Eikelboom JW. Red blood cell storage and in-hospital mortality: a secondary analysis of the INFORM randomised controlled trial. The Lancet Hematology. 2017 Nov;4(11):e544-e552.
  12. McEneny-King A, Chelle P, Henrard S, Hermans C, Iorio A, Edginton AN. Modeling of Body Weight Metrics for Effective and Cost-Efficient Conventional Factor VIII Dosing in Hemophilia A Prophylaxis. Pharmaceutics. 2017 Oct 17;9(4). pii: E47.
  13. Mian H, Warkentin TE, Sheppard JI, MacDonald A, Linkins LA, Benger A, Foley R. Autoimmune HIT due to apheresis catheter heparin flushes for stem-cell harvesting before autotransplantation for myeloma. Blood. 2017 Oct 5;130(14):1679-82.  
  14. Shih AW, Sheppard JI, Warkentin TE. Platelet count recovery and seroreversion in immune HIT despite continuation of heparin: further observations and literature review. Thromb Haemost. 2017 Oct 5;117(10):1868-74.
  15. Nossair FF, Chan HHW, Gantioqui J, Atkinson HM, Berry LR, Chan AKC. In vitro assessment of the effect of dabigatran on thrombosis of adult and neonatal plasma: Comparisons using thromboelastography and microscopic visualization of fibrin clot structure. Blood Coagulation and Fibrinolysis. 2017 Oct;28(7):551-7.
  16. Heddle NM. From cytokines to pragmatic designs: changing paradigms. Transfusion. 2017 Oct;57(10): 2298-306.
  17. Zeller MP, Barty RL, Aandahl A, Apelseth TO, Callum J, Dunbar NM, Elahie A, Garritsen H, Hancock H, Kutner JM, Manukian B, Mizuta S, Okuda M, Pagano MB, Poglod R, Rushford K, Selleng K, Sorensen CH, Sprogoe U, Staves J, Weiland T, Wendel S, Wood EM, van de Watering L, van Wordragen-Vlaswinkel M, Ziman A, Jan Zwaginga J, Murphy MF, Heddle NM, Yazer MH, BEST Collaborative. An international investigation into O red blood cell unit administration in hospitals: The Group O Utilization Patterns (GROUP) Study. Transfusion. 2017 Oct;57(10):2329-37.
  18. Price D, Arnold DM, Seekins N, Peter J, Cooke, L and Yu-Hin Siu, H. A Novel Primary –Specialist Care collaborative Demonstration Project to improve the Access and Healthcare of Medically Complex Patients. Chronic Illness. 2017 Sep;13(3):151-70.
  19. Hepponstall M, Chan A, Monagle P. Anticoagulation therapy in neonates, children and adolescents. Blood Cells, Molecules, & Diseases. 2017 Sep;67:41-7. 
  20. Chang GT, Atkinson HM, Berry LR, Chan AKC.  Inhibition of plasmin generation in plasma by heparin, low molecular weight heparin and a covalent antithrombin-heparin complex. Blood Coagulation and Fibrinolysis. 2017 Sep;28(6):431-7.   
  21. Piran S, Delaney J, Schulman S, Salib M, Panju M, Pai M. Direct Oral Anticoagulants in the Real World:  Insights Into Appropriate Prescribing and Medication Use. Can J Nursing Res. 2017 Sep;49(3):105-7. 
  22. Ning S, Warkentin TE. IV immunoglobulin for autoimmune heparin-induced thrombocytopenia. Chest. 2017 Sep;152(3):453-5. [Editorial commentary on: Padmanabhan A, Jones CG, Pechauer SM, Curtis BR, Bougie DW, Irani MS, Bryant BJ, Alperin JB, Deloughery TG, Mulvey KP, Dhakal B, Wen R, Wang D, Aster RH. IVIg for treatment of severe refractory heparin-induced thrombocytopenia. Chest. 2017 Sep;152(3):478-85.
  23. Lawson W, Uy M, Strike K, Iorio A, Stein N, Koziol L, Chan A. Point of care ultrasound in haemophilia: Building a strong foundation for clinical implementation. Haemophilia. 2017 Sep;23(5):648-51. 
  24. Peyvandi F, Makris M, Collins P, Lillicrap D, Pipe SW, Iorio A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders. Minimal dataset for post-registration surveillance of new drugs in hemophilia: a communication from the SSC of the ISTH. J Thromb Haemost. 2017 Sep;15(9): 1878-1881.  
  25. Poudel DR, Ghimire S, Dhital R, Forman D, Warkentin TE. Spontaneous HIT syndrome post-knee replacement surgery with delayed recovery of thrombocytopenia: a case report and literature review. Platelets. 2017 Sep;28(6):614-20.
  26. Chu DK, Hillis CM, Leong DP, Anand SS, Siegal DM. Benefits and Risks of Antithrombotic Therapy in Essential Thrombocythemia: A Systematic Review. Ann Intern Med. 2017 Aug 31;167(3):170-180.
  27. Warkentin TE, Pai M, Linkins LA. Direct Oral Anticoagulants for Treatment of HIT: Update of Hamilton  Experience and Literature Review. Blood. 2017 Aug 31; 130(9):1104-13. 
  28. Patriquin C, Clark WF, Pavenski K, Arnold DM, Rock G, Foley SR, Canadian Apheresis Group. How we treat thrombotic thrombocytopenia purpura: Results of a Canadian TTP practice survey. J Clin Apher. 2017 Aug;32(4):246-56. 
  29. Raschke RA, Gallo T, Curry SC, Whiting T, Padilla-Jones A, Warkentin TE.  Clinical effectiveness of a Bayesian algorithm for the diagnosis and management of heparin-induced thrombocytopenia. J Thromb Haemost. 2017 Aug;15(8):1640-5. 
  30. Martin RMG, Ricci MJ, Foley R, Mian HS.The relationship of CD34+ dosage and platelet recovery following high dose chemotherapy and autologous CD34+ rein fusion in multiple myeloma. Transfus Apher Sci. 2017 Aug;56(4):552-7. 
  31. Ezekwudo DE, Chacko R, Gbadamosi B, Batool S, Gaikazian S, Warkentin TE, Sheppard JI, Jaiyesimi I. Apixaban for treatment of confirmed heparin-induced thrombocytopenia: a case report and review of literature. Exp Hematol Oncol. 2017 Jul 14;6:21.
  32. Arnold DM, Vrbensky JR, Karin N, Smith JW, Liu Y, Ivetic N, Kelton JG, Nazy I. The effect of rituximab on anti-platelet autoantibody levels in patients with immune thrombocytopenia. Br J Haematol. 2017 Jul;178(2):302-7.
  33. Iorio A, Fischer K, Makris M. Large scale studies assessing anti‐factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more. Br J Haematol. 2017 Jul;178(1):20-31.
  34. Iorio A, Edginton AN. Exploring some intersections between pharmacokinetics, factor VIII measurement and human morphometrics-impact of recent advances in haemophilia study design on our understanding of optimal haemophilia treatment. Haemophilia. 2017 Jul;23(4):488-90.
  35. Keepanasseril A, Stoffman J, Bouskill V, Carcao M, Iorio A, Jackson S, Association of Hemophilia Centre Directors of Canada (AHCDC). Switching to extended half-life products in Canada - preliminary data. Haemophilia. 2017 Jul;23(4):e365-7. 
  36. Boonyawat K, Caron F, Li A, Chai‐Adisaksopha C, Lim W, Iorio A, Lopes RD, Garcia D, Crowther MA. Association of body weight with efficacy and safety outcomes in phase III randomized controlled trials of direct oral anticoagulants: a systematic review and meta‐analysis. J Thromb and Haemost. 2017 Jul;15(7):1322-33.
  37. Husseinzadeh HD, Gimotty PA, Pishko AM, Buckley M, Warkentin TE, Cuker A. Diagnostic Accuracy of IgG‐Specific Versus Polyspecific Enzyme‐Linked Immunoassay for the Diagnosis of Heparin‐Induced Thrombocytopenia: a Systematic Review and Meta‐Analysis. J Thromb Haemost. 2017 Jun;15(6):1203-12.
  38. Iorio A, Fischer K, Blanchette V, Rangarajan S, Young G, Morfini M. Tailoring treatment of haemophilia B: accounting for the distribution and clearance of standard and extended half-life FIX concentrates. Thromb Haemost. 2017 Jun 2;117(6):1023-30. 
  39. Weiskopf RB, Cook RJ. Demonstrating therapeutic equivalence of a new and established pharmaceutical or intervention: a guide for the non-statistician. Transfusion, 2017 Jun;57(6):1343-6.
  40. Caron F, Leong DP, Hillis C, Fraser G, Siegal D. Current understanding of bleeding with ibrutinib use: a systematic review and meta-analysis. Blood Advances. 2017 May 9;1(12):772-778.
  41. Athale U, Laverdiere C, Nayiager T, Delva YL, Foster G, Thabane L, Chan AKC. Evaluation for inherited and acquired prothrombotic defects predisposing to symptomatic thromboembolism in children with acute lymphoblastic leukemia: A protocol for a prospective, observational, cohort study. BMC Cancer. 2017 May 4;17(1):313.
  42. Wang TF, Dawson JE, Forman-Kay JD, Kahr WH, Williams S, Chan AK, Kumar R. Molecular structural analysis of a novel and de-novo mutation in the SERPINC1 gene associated with type 1 anithtrombin deficiency. British Journal of Haematology. 2017 May;177(4):654-656.   
  43. Iorio A, Iserman E, Blanchette V, Dolan G, Escuriola Ettingshausen C, Hermans C, Negrier C, Oldenburg J, Reininger A, Rodriguez‐Merchan C, Spannagl M. Target plasma factor levels for personalized treatment in haemophilia: a Delphi consensus statement. Haemophilia. 2017 May;23(3):e170-79.
  44. Iorio A, Krishnan S, Myrén KJ, Lethagen S, McCormick N, Yermakov S, Karner P. Indirect comparisons of efficacy and weekly factor consumption during continuous prophylaxis with recombinant factor VIII Fc fusion protein and conventional recombinant factor VIII products. Haemophilia. 2017 May;23(3):408-16.
  45. Iorio A. Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development. Haemophilia. 2017 May;23(3):350-2.
  46. Wassef A, Lim W, Wu C. Indications, complications and outcomes of inferior vena cava filters: a retrospective study. J Thrombi Haemost. 2017 May;153:123-128.   
  47. Warkentin TE, Sheppard JI, Linkins LA, Arnold DM, Nazy I. Performance characteristics of an automated latex immunoturbidimetric assay (Hemosil HIT- Ab (PF4H) for the diagnosis of immune heparin induced thrombocytopenia. Thromb Res. 2017 May;153:108-117.
  48. Barty RL, Pai M, Liu Y, Arnold DM, Cook RJ, Zeller MP, Heddle NM. Group O RBCs: where is universal donor blood being used. Vox Sang. 2017 May;112(4):336-42.
  49. Middeldrop S, Iorio A. Oral contraceptive use is a provoking factor for venous thromboembolism. BMJ. 2017 Apr 27;357:j2073. 
  50. Staibano P, Arnold DM, Bowdish DM, Nazy I. The unique immunological features of heparin‐induced thrombocytopenia. Br J Haematol. 2017 Apr 1;177(2):198-207.
  51. Thachil J, Warkentin TE. How do we approach thrombocytopenia in critically ill patients? Br J Haematol. 2017 Apr;177(1):27-38.
  52. Iorio A, Krishnan S, Myrén KJ, Lethagen S, McCormick N, Yermakov S, Karner P. Continuous prophylaxis with recombinant factor IX Fc fusion protein and conventional recombinant factor IX products: comparisons of efficacy and weekly factor consumption. J Med Econ. 2017 Apr;20(4):337-44.
  53. Shih AW, Jamula E, Diep C, Lin Y, Armali C, Heddle NM. Traore A, Doherty J, Shah N, Hillis CM. Audit of provincial IVIG Request Forms and efficacy documentation in four Ontario tertiary care centres. Transfusion Medicine. 2017 Apr 1;27(2):122-31.  
  54. Korte, W, Poon MC, Iorio A, Makris M. Thrombosis in inherited firbrinogen disorders. Transfus Med Hemother. 2017 Apr;44(2):70-6. 
  55. Chai-Adisaksopha C, Alexander PE, Guyatt G, Crowther MA, Heddle NM, Devereaux PJ, Ellis M, Roxby D, Sessler DI, Eikelboom JW. Mortality outcomes in patients transfused with fresher versus older red blood cells: A meta-analysis. Vox Sanguinis. 2017 Apr;112(3): 268-78. 
  56. Winkelhorst D, Murphy MF, Greinacher A, Shehata N, Bakchoul T, Massey E, Baker J, Lieberman L, Tanael D, Hume H, Arnold DM, Baidya S, Bertrand G, Bussel J, Kjaer M, Kaplan C, Kjeldsen-Kragh J, Oepkes D, Ryan G. Anenatal management in fetal neonatal alloimmune thrombocytopenia: a systematic review. Blood. 2017 Mar 16;129(11):1538-47.
  57. Heddle NM, Cook RJ, Arnold DM, Holst LB, Petersen MW, Haase N, Perner A, Wetterslev J, Prudent M, Tissot JD, Lion N. Short-Term versus Long-Term Blood Storage. N Engl J Med. 2017 Mar 16;376(11):1093-4.
  58. Shapiro RM, Zeller MP, Warkentin TE. Sepsis and persisting neutropenia in a drug addict. Am J Hematol. 2017 Mar;92(3):312-6.
  59. Iorio A, Barbara AM, Makris M, Fischer K, Castaman G, Catarino C, Gilman E, Kavakli K, Lambert T, Lassila R, Lissitchkov T. Natural history and clinical characteristics of inhibitors in previously treated haemophilia A patients: a case series. Haemophilia. 2017 Mar 1;23(2):255-63.
  60. Delaney M, Wikman A, van de Watering L, Schonewille H, Verdoes JP, Emery SP, Murphy MF, Staves J, Flach S, Arnold DM, Kaufman RM, Ziman A, Harm SK, Fung M, Eppes CS, Dunbar NM, Buser A, Meyer E, Savoia H, Abeysinghe P, Heddle N, Tinmouth A, Traore AN, Yazer MH; BEST Collaborative. Blood group antigen matching influence on gestational outcomes (AMIGO) study. Transfusion. 2017 Mar;57(3):525-32. 
  61. Chai-Adisaksopha C, Linkins LA, ALKindi SY, Cheah M, Crowther MA, Iorio A. Outcomes of low-molecular-weight heparin treatment for venous thromboembolism in patients with primary and metastatic brain tumours. Thromb Haemost. 2017 Feb 28;117(3):589-94.  
  62. Berger RE, Pai M, Rajasekhar A. Thromboprophylaxis after Knee Arthroscopy. N Engl J Med. 2017 Feb 9;376(6):580-3.  
  63. van Vulpen LF, Saccullo G, Iorio A, Makris M. The current state of adverse event reporting in hemophilia. Expert Rev Hematol. 2017 Feb;10(2):161-8.
  64. Ziman A, Cohn C, Carey PM, Dunbar NM, Fung MK, Greinacher A, Stanworth S, Heddle NM, Delaney M, and the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Warm-reactive (immunoglobulin G) autoantibodies and laboratory testing best practices: Review of the literature and survey of current practice. Transfusion. 2017 Feb;57(2):463-477.  
  65. Weiskopf RB and Cook RJ. Understanding non-inferiority trials and tests for the non-statistician: when to use them and how to interpret them. Transfusion. 2017 Feb;57(2):240-3.  
  66. Rock G, Clark W, Foley R, Huang S, Laroche V, Klassen J, Patriquin C, Pavenski K; CAG TTP Working Group Members. TTP: One of the TMA's-How to sort it out. Transfus Apher Sci. 2017 Feb;56(1):57-8.
  67. Arnold DM, Patriquin CJ, Nazi I. Thrombotic microangiopathies: a general approach to diagnosis and management. CMAJ. 2017 Jan 30;189(4):E153-9.
  68. Sun, J., Zhao, Y., Yang, R., Guan, T., Iorio, A. and the Chinese HERO study group. The demographics, treatment characteristics and quality of life of adult people with haemophilia in China - results from the HERO study. Haemophilia. 2017 Jan;23(1):89-97.   
  69. Zeller M, Arnold DM, Al-Habsi K, Cserti-Gazdewich C, Delage G, Lebrun A, Heddle NM. Paroxysmal cold hemoglobinuria: A difficult diagnosis in adult patients. Transfusion. 2017 Jan;57(1):137-143. 
  70. Refaei M, Xing L, Lim W, Crowther M, Boonyawat K. Management of Venous Thromboembolism in Patients with Hereditary Antithrombin Deficiency and Pregnancy: Case Report and Review of the Literature. Case Reports in Hematology. 2017.
  71. Samuelson BT, Cuker A, Siegal DM, Crowther MA, Garcia D. Laboratory Assessment of the Anticoagulant Activity of Direct Oral Anticoagulants (DOACs): A Systematic Review. Chest. 2017 Jan;151(1):127-138.
  72. Iorio A, Stonebraker JS, Brooker M, Soucie JM; Data and Demographics Committee of the World Federation of Hemophilia. Measuring the quality of haemophilia care across different settings: a set of performance indicators derived from demographics data. Haemophilia. 2017 Jan;23(1):e1-7.
  73. Arnold DM, Lauzier F, Albert M, et al. The association between platelet transfusions and bleeding in critically ill patients with thrombocytopenia. Res Practice Thromb Haemost. 2017;1:103-111.
  74. Mitra S, Chan AKC, Paes BA, on behalf of the Thrombosis and Hemostasis in Newborns (THiN) Group. The association of platelets with failed patent ductus arteriosus closure after primary course of indomethacin or ibuprofen:  A systematic review and a meta-analysis. Journal of Maternal-Fetal & Neonatal Medicine. 2017 Jan;30(2):127-133.   

2016

PLACEHOLDER TITLE

 

  1. Statistical Analysis for the INFORM Study.
  2. Nazy I, Moore JC, Clare R, Smith JW, Ivetic N, D'Spuza V, Kelton JG, Arnold DM. Autoantibodies to thrombopoietin Receptor in Patients with Immune Thrombocytopenia. Blood. 2016;128:2548.
  3. Iorio A, Keepanasseril A, Foster G, Navarro-Ruan T, McEneny-King A, Edginton AN, Thabane L; WAPPS-Hemo co-investigator network. Development of a Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo): Study Protocol. JMIR Res Protoc. 2016 Dec 15;5(4):e239.
  4. Boonyawat K, Caron F, Li A, Chai-Adisaksopha C, Lim W, Alfonso I, Lopes RD, Garcia D, Crowther M. Association of BW with Thromboembolic and Bleeding Outcomes in Phase III Randomized Controlled Trials of Direct Oral Anticoagulants: Systematic Review and Meta-Analysis. Blood. 2016 Dec;128(22):88.
  5. McEneny-King A, Foster G, Iorio A, Edginton AN. Data Analysis Protocol for the Development and Evaluation of Population Pharmacokinetic Models for Incorporation into the Web-Accessible Population Pharmacokinetic Service – Hemophilia (WAPPS-Hemo). JMIR Res Protoc. 2016 Dec 7;5(4):e232.
  6. Heddle NM, Cook RJ, Arnold DM, Liu Y, Barty RL, Crowther MA, Devereaux PJ, Hirsh J, Warkentin TE, Webert KE, Roxby D, Sobieraj-Teague M, Kurz A, Sessler DI, Figueroa P, Ellis M, Eikelboom JW. Effect of short-term vs. long-term blood storage on mortality after transfusion. N Engl J Med. 2016 Nov 17; 375:1937-1945.
  7. Carson JL, Guyatt G, Heddle NM, Grossman BJ, Cohn CS, Fung MK, Gernsheimer T, Holcomb JB, Kaplan LJ, Katz LM, Peterson N, Ramsey G, Rao SV, Roback JD, Shander A, Tobian AA. Clinical practice guidelines from the AABB: Red blood cell transfusion thresholds and storage. JAMA. 2016 Nov 15; 316(19):2025-35.
  8. Warkentin TE. Acute intraoperative HIT during heart surgery: why so rare? Thromb Res. 2016 Oct; 146:110-112.
  9. Spradbrow J, Cohen R, Lin Y, Armali C, Collins A, Cserti‐Gazdewich C, Lieberman L, Pavenski K, Pendergrast J, Webert K, Callum J.Evaluating appropriate red blood cell transfusions: a quality audit at 10 Ontario hospitals to determine the optimal measure for assessing appropriateness. Transfusion. 2016 Oct 1; 56(10):2466-76.
  10. Tobian AA, Heddle NM, Wiegmann TL, Carson JL. Red blood cell transfusion: 2016 clinical practice guidelines from AABB. Transfusion. 2016 Oct; 56(10):2627-2630.
  11. Warkentin TE. B cells, PF4/heparin complexes, and complement. Blood. 2016 Oct; 128(14): 1789-1799.
  12. Solh Z, Athale U, Arnold DM, Cook RJ, Foley R, Heddle NM. Transfusion-related alloimmunization in children: Epidemiology and effects of chemotherapy. Vox Sang. 2016 Oct; 111(3):299-307.
  13. Bakchoul T, Greinacher A, Warkentin TE. (2016). Heparin-induced thrombocytopenia in 2017 and beyond. Thromb Haemost. 2016 Oct; 116(5): 781-782.
  14. Chai-Adisaksopha C, Hillis C, Siegal DM, Movilla R, Heddle NM, Iorio A, Crowther M. Prothrombin complex concentrates versus fresh frozen plasma for warfarin reversal. A systematic review and meta-analysis. Thromb Haemost. 2016 Oct 28; 116(5):879-890.
  15. Mithoowani S, Gregory-Miller K, Goy J, Miller MC, Wang G, Noroozi N, Kelton JG, Arnold DM. High-dose dexamethasone compared with prednisone for previously untreated primary immune thrombocytopenia: a systematic review and meta-analysis. Lancet Hematol. 2016 Oct; 3(10): e489-e496.
  16. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia (HIT) and its differentiation from non-HIT thrombocytopenia. Thromb Haemost. 2016 Oct; 116(5): 813-822.
  17. Rebelo JM, Sommer DD, Smriti, N, Choong K, Chan AKC, Fulford, M. To anticoagulate? Controversy in the management of thrombotic complications of head & neck infections. International Journal of Paediatric Otorhinolaryngology. 2016 Sep;88:129-35. 
  18. Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A, Bronson MD, Lu G, Conley  PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon  J, Goodman S, Leeds J, Wiens BL, Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M, ANNEXA-4 Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa  Inhibitors. N Engl J Med. 2016 Sep 22;375(12):1131-41.
  19. Bakchoul T, Jouni R, Warkentin TE. Protamine (heparin)-induced thrombocytopenia: a review of the serological and clinical features associated with anti-protamine/heparin antibodies. J Thromb Haemost. 2016 Sep; 14(9): 1685-1695.
  20. Warkentin TE, Greinacher A. Management of heparin-induced thrombocytopenia. Curr Opin Hematol. 2016 Sep; 23(5): 462-470.
  21. Ning S, Barty R, Liu Y, Heddle NM, Rochwerg B, Arnold DM. Platelet transfusion practices in the intensive care unit: Data from a large transfusion registry. Chest. 2016 Sep; 150(3):516-23.
  22. Sun D, Shehata N, Ye, XY, Gregorovich S, De France B, Arnold DM, Shah PS, Malinowski AK. Corticosteroids compared with intravenous immunoglobulin for the treatment of immune thrombocytopenia in pregnancy. Blood. 2016 Sep 8; 128(10): 1329-35.
  23. Solh Z, Chan AKC, Heddle NM. Transfusion premedication practices among pediatric health care practitioners in Canada: Results of a national survey. Transfusion. 2016 Sep; 56(9):2296-302.
  24. Shih AW, Bhagirath VC, Heddle NM, Acker JP, Liu Y, Eikelboom JW, Liaw PC. Quantification of Cell-Free DNA in Red Blood Cell Units in Different Whole Blood Processing Methods. Journal of blood transfusion. 2016 Sep 27;2016.
  25. Bhatt MD, Paes BA, Chan AK. How to use unfractioned heparin to treat neonatal thrombosis in clinical practice. Blood Coagul Fibrinolysis. 2016 Sep; 27(6):605-614,
  26. Warkentin TE, Greinacher A, Bux J. Letter of response to Peters and Vlaar commentary. Transfusion. 2016 Sep; 56(9): 2395-2397.
  27. Warkentin TE.  Platelet activation testing for heparin-induced thrombocytopenia antibodies: a problem that needs fixing? Chest. 2016 Sep; 150(3): 478-480.
  28. Couban S, Mahmoud A, Lachance S, Walker I, Toze, CL Toze, Morel R, Lipton J, Lee SJ, Szer J, Doocey R, Lewis I, Lalancette M, Almohareb F, Chaudhri N, Ivison S, Levings M, Devins G, Szwajcer D, Foley R, Smith CA, Panzarella T, Kerr H, Kariminia A, Schultz K. Filgrastim-stimulated bone marrow compared with filgrastim-mobilized peripheral blood for allografting in patients with hematologic malignancies. Biology of Blood and Marrow Transplantation. 2016 Aug;22(8):1410-15.
  29. Salib M, Clayden R, Clare R, Wang G, Warkentin TE, Crowther MA, Lim W, Nazi I, Kelton JG, Arnold DM. Difficulties in establishing the diagnosis of immune thrombocytopenia: An agreement study. Am J Hematol. 2016 Aug; 91(8): E 327-9.
  30. Bakchoul T, Warkentin TE. Safe bridging to warfarin heparin-induced thrombocytopenia. Thromb Res. 2016 Aug; 144: 229-233.
  31. Waters AM, Caboot JB, Verhovsek MM, Harper DP, Forouhar MA. Hb Grifton [α87(F8)His→Pro; HBA1: C.263A > C (or HBA2)] causes abnormal pulse oximetry measurements. Hemoglobin. 2016 Aug;40(4):257-9.
  32. Leong DP, Caron F, Hillis C, Duan A, Healey JS, Fraser G, Siegal DM. The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis. Blood. 2016 Jul 7;128(1):138-40.
  33. Park CK, Paes BA, Nagel K, Chan AK, Murthy P; Thrombosis, Hemostasis in Newborns (THiN) Group. Neonatal central venous catheter thrombosis: diagnosis, management and outcome. Blood Coagul Fibrinolysis. 2016 Jul 29. [Epub ahead of print]
  34. Lane SJ, Sholapur NS, Yeung CH, Iorio A, Heddle NM, Sholzberg M, Pai M. Understanding stakeholder important outcomes and perceptions of equity, acceptability and feasibility of a care model for haemophilia management in the US: A qualitative study. Haemophilia. 2016 Jul; 22(Suppl. 3):23-30.
  35. Ward R, Simpson E, Verhovsek M. Decisions: A 19-year-old woman with sickle cell pain and pain. CMAJ. 2016 Jul 12; 188(10):745-6.
  36. Yeung CHT, Santesso N, Pai M, Kessler C, Key NS, Makris M, Navarro-Ruan T, Soucie MJ, Schünemann HJ, Iorio A. Care models in the management of haemophilia: a systematic review. Haemophilia. 2016 July; 22(S3):31-40.
  37. Yeung CHT, Santesso N, Zeraatkar D, Wang A, Pai M, Sholzberg M, Schünemann HJ, Iorio A. Integrated multidisciplinary care for the management of chronic conditions in adults: an overview of reviews and an example of using indirect evidence to inform clinical practice recommendations in the field of rare diseases. Haemophilia. 2016 July; 22(S3):41-50.
  38. Sholapur NS, Hamilton K, Butler L, Heddle NM, Arnold DM. An evaluation of overall effectiveness and treatment satisfaction with intravenous immunoglobulin among patients with immune thrombocytopenia. Transfusion. 2016 Jul; 56(7):1739-44.
  39. Warkentin TE, Anderson JAM. How I treat patients with a history of heparin-induced thrombocytopenia. Blood. 2016 July; 128(3): 348-359.
  40. Khan R, Chan AKC, Mondal TK, Paes BA, on behalf of the Thrombosis and Hemostasis in Newborns (THiN) Group. Patent foramen ovale and stroke in childhood: A systematic review of the literature. Eur J Paediatric Neurol. 2016 Jul; 20(4):500-511,
  41. Pai M, Key NS, Skinner M, Curtis R, Feinstein M, Kessler C, Lane SJ, Makris M, Riker E, Santesso N, Soucie JM, Yeung CHT, Iorio Aand Schünemann HJ. NHF-McMaster Guideline on Care Models for Haemophilia Management. Haemophilia. 2016 July; 22(S3):6-16.
  42. Pai M, Santesso N, Yeung CHT, Lane SJ, Schünemann HJ and Iorio A. Methodology for the development of the NHF-McMaster Guideline on Care Models for Haemophilia Management. Haemophilia. 2016 July; 22(S3):17-22. 
  43. Chai-Adisaksopha C, Iorio A, Hillis C, Lim W, Crowther M. A systematic review of using and reporting survival analyses in acute lymphoblastic leukemia literature. BMC hematology. 2016 Jun 8;16(1):1.  
  44. Chen K, Agarwal A, Tassone MC, Shahjahan N, Walton M, Chan A, Mondal T.  Risk factors for central venous catheter-related thrombosis in children: A retrospective analysis. Blood Coagulation and Fibrinolysis. 2016 Jun;27(4):384-8.   
  45. AABB Clinical Transfusion Medicine Committee, Heddle NM, Boeckh M, Grossman B, Jacobson J, Kleinman S, Tobian AA, Webert KE, Wong EC, Roback JD. AABB committee report: Reducing transfusion transmitted cytomegalovirus infections. Transfusion. 2016 Jun; 56(6 Pt 2):1581-7.
  46. Sarhangian V, Abouee-Mehrizi H, Baron O, Berman O, Heddle NM, Barty RL. Reducing the age of transfused red blood cells in hospitals: Ordering and allocation policies. Vox Sanguinis. 2016 May; 110(4):385-92.
  47. Heddle NM, Arnold DM, Acker JP, Liu Y, Barty RL, Eikelboom JW, Webert KE, Hsia CC, O’Brien SF, Cook RJ. Red blood cell processing methods and in-hospital mortality: A transfusion registry cohort study. Lancet Haematol. 2016 May; 3(5):e246-54.
  48. Solh Z, Breakey V, Murthy P, Smith JW, Arnold DM. Triplets with neonatal alloimmune thrombocytopenia due to antibodies against human platelet antigen 1a. Transfusion. 2016 May; 56(5): 1168-1170.
  49. Ivetic N, Nazi I, Karim N, Clare R, Smith JW, Moore JC, Hope KJ, Kelton JG, Arnold DM. Producing megakaryocytes from a human peripheral blood source. Transfusion. 2016 May; 56(5): 1066-74.
  50. Walsh GM, Shih AW, Solh Z, Golder M, Schubert P, Fearon M,Sheffield WP. Blood‐borne Pathogens: A Canadian Blood Services Centre for Innovation Symposium. Transfusion Medicine Reviews. 2016 Apr;30(2):53-68.
  51. Lin HX, Sjaarda J, Dyck J, Stringer R, Hillis C, Harvey M, Carter R, Ainsworth P, Leber B, Pare G, Sadikovic B. Gender and BCR-ABL transcript type are correlated with molecular response to imatinib treatment in patients with chronic myeloid leukemia. Eur J Haematol. 2016 Apr;96(4):360-6.
  52. Jaffer AM, Wang G, Barty RL, Shih AW. Evaluation of CONSORT compliance in TRANSFUSION. Transfusion. 2016 Apr;56(4):789-90. 
  53. Heddle NM, Ness PM. CONSORT and clinical trial reporting: Room for improvement. Editorial. Transfusion. 2016 Apr; 56(4):781-3.
  54. Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, Wu C, Nazi I, Crowther MA. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. J Thromb Haemost. 2016 Apr; 14(6):1206-10.
  55. Warkentin TE. Demand on-demand testing for the diagnosis of heparin-induced thrombocytopeniaThromb Res. 2016 Apr; 140: 163-164.
  56. Schünemann HJ, Ventresca M, Crowther M, Briel M, Zhou Q, Garcia D, Lyman G, Noble S, Macbeth F, Griffiths G, DiNisio M, Iorio A, Beyene J, Mbuagbaw L, Neumann I, Van Es N, Brouwers M, Brozek J, Guyatt G, Levine M, Moll S, Santesso N, Streiff M, Baldeh T, Florez I, Gurunlu Alma O, Solh Z, Ageno W, Marcucci M, Bozas G, Zulian G, Maraveyas A, Lebeau B, Buller H, Evans J, McBane R, Bleker S,  Pelzer U, Akl EA; IPDMA heparin use in cancer patients research group. Use of heparins in patients with cancer: individual participant data meta-analysis of randomised trials study protocol. BMJ Open. 2016 Apr 29; 6(4).
  57. Gray N, Newbold KB, Lane SJ, Heddle NM, Webert KE, Eyles J. Public perceptions of pathogen reduction technology in the Canadian donor blood supply. ISBT Science Series. 2016 Apr; 11(1):14-23.
  58. Qadri SM, Donkor DA, Bhakta V, Eltringham-Smith LJ, Dwivedi DJ, Moore JC, Pepler L, Ivetic N, Nazi I, Fox-Robichaud AE, Liaw PC, Sheffield WP. Phosphatidylserine externalization and procoagulant activation of erythrocytes induced by Pseudomonas aeruginosa virulence factor pyocyanin. J Cell Mol Med. 2016 Apr; 20(4):710-20.
  59. Fonseca A, Nagel K, Decker K, Pukulakatt M, Pai M, Walton M, Chan AK. Central venous access device insertion and perioperative management of patients with severe haemophilia A: A local experience. Blood Coagulation and Fibrinolysis. 2016 Mar;27(2):156-9.
  60. Tseng E, Crowther MA, Hillis CM. Bridging anticoagulation for interruption of warfarin in a patient with atrial fibrillation. CMAJ. 2016 Mar 15;188(5):361-2. 
  61. Pai M, Cook R, Barty RL, Eikelboom J, Lee Ker-Ai, Heddle NM. Exposure to ABO non- identical blood associated with increased in-hospital mortality in patients with group A blood. Transfusion. 2016 Mar; 56(3):550-7.
  62. Bates SM, Takach Lapner S, Douketis JD, Kearon C, Julian J, Parpia S, Schulman S, Weitz JI, Linkins LA, Crowther M, Lim W, Spencer FA, Lee AY, Gross PL, Ginsberg J. Rapid quantitative D-dimer to exclude pulmonary embolism: A prospective cohort management study. J Thromb Haemost. 2016 Mar;14(3):504-9.
  63. Dzik WS, Ziman A, Cohen C, Pai M, Lozano M, Kaufman RM, Delaney M, Selleng K, Murphy MF, Hervig T, Yazer M; Biomedical Excellence for Safer Transfusion Collaborative. Survival after ultramassive transfusion: a review of 1360 cases. Transfusion. 2016 Mar; 56(3):558-63.
  64. Walker I, Panzarella T, Couban S, Couture F, Devins G, Elemary , Gallagher G, Kerr H, Kuruvilla J, Lee S, Moore J, Nevel T, Popradi G, Roy J, Schultz K, Szwajcer D, Toze C, Foley R. Pretreatment with anti-thymocyte globulin versus no anti-thymocyte globulin in patients with haematological malignancies undergoing haemopoietic cell transplantation from unrelated donors: a randomized, controlled, open-label, phase 3, multicenter trial. Lancet Oncol. 2016 Feb;17:164-73.   
  65. Manlhiot C, Gruenwald CE, Holtby HM, Brandao LR, Chan AK, Van Arsdell GS, McCrindle BW. Challenges with heparin-based anticoagulation during cardiopulmonary bypass in children: Impact of low antithrombin activity. Journal of Thoracic and Cardiovascular Surgery. 2016 Feb;151(2):444-50.
  66. Crowther MA, Lim W. Use of low molecular weight heparins in patients with renal failure; time to re-evaluate our preconceptions. J Gen Intern Med. 2016 Feb;31(2):147-8.   
  67. Elkind MSV, Hills NK, Glaser CA, Lo WD, Amlie-Lefond C, Dlamini N, Kneen R, Hod EA, Wintermark m, deVeber GA, Fullerton HJ; and the VIPS Investigators.  Herpesvirus infections and childhood arterial ischemic stroke: Results of the VIPS study. Circulation. 2016 Feb 23;133(8):732-41.   
  68. Warkentin TE. Knee replacement and HIT without heparin. Blood. 2016 Feb 25; 127 (8): 961-962.
  69. Dolan G, Iorio A, Jokela V, Juusola K, Lassila R. Haemophilia in a real-world  setting: the value of clinical experience in data collection. Eur J Haematol. 2016 Feb; 96 Suppl 82:3-9.
  70. Warkentin TE, Pai M. Shock, acute DIC, and micro vascular thrombosis - is “shock liver” the unrecognized provocateur of ischemic limb necrosis? J Thromb Haemost. 2016 Feb; 14(2):231-5.
  71. Eikelboom JW, Cook RJ, Barty RL, Liu Y, Arnold DM, Crowther MA, Devereaux PJ, Ellis M, Figueroa P, Gallus A, Hirsh J, Kurz A, Roxby D, Sessler DI, Sharon Y, Sobieraj-Teague M, Warkentin TE, Webert KE, Heddle NM. Rationale and design of the Informing Fresh versus Old Red Cell Management (INFORM) Trial: An international pragmatic randomized trial. Transfusion Medicine Reviews. 2016 Jan; 30(1):25-29.
  72. Zeller MP, Sherbino J, Whitman L, Skeate R, Arnold DM. Design and Implementation of a Competency-Based Transfusion Medicine Training Program in Canada. Transfus Med Rev. 2016 Jan; 30(1):30-6.
  73. Zeller MP, Heddle NM, Kelton JG, Hamilton K, Wang G, Sholapur N, Carruthers J, Hsia C, Blais N, Toltl L, Hamm C, Pearson M-A,Arnold DM. Effect of a thrombopoietin receptor agonist on use of intravenous immune globulin in patients with immune thrombocytopenia. Transfusion. 2016 Jan; 56(1):73-79.
  74. Hillis CM, Shih A, Heddle NM. Best practices in differential diagnosis and reporting of acute transfusion reactions. International Journal of Clinical Transfusion Medicine. 2016 Jan; 4:1-14.
  75. Ypma PF, van der Meer PF, Heddle NM, van Hilten JA, Stijnen T, Middelburg RA, Hervig T, van der Bom JG, Brand A, Kerkhoffs J-L, for the PREPAReS Study Group. A study protocol for a randomized controlled trial evaluating clinical effects of platelet transfusion products: The Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open. 2016 Jan 5; 6:e010156.
  76. Thiele T, Hron G, Kellner S, Wasner C, Westphal A, Warkentin TE, Greinacher A, Selleng K. Thrombin generation, ProC®Global, prothrombin time and activated partial thromboplastin time in thawed plasma stored for seven days and after methylene blue/light pathogen inactivation. Blood Transfus. 2016 Jan; 14 (1): 66-72.
  77. Stevens SM, Woller SC, Bauer KA, Kasthuri R, Cushman M, Streiff M, Lim W, Douketis JD. Guidance for the evaluation and treatment of hereditary and acquired thrombophilia. J Thromb Thrombolysis. 2016 Jan; 41(1):154-64.
  78. Fischer K, Iorio A, Hollingsworth R, Makris M; EUHASS collaborators. FVIII inhibitor development according to concentrate: data from the EUHASS registry excluding overlap with other studies. Haemophilia. 2016 Jan;22(1):e36-8.
  79. Alexander PE, Barty R, Fei Y, Vandvik PO, Pai M, Siemieniuk RA, Heddle NM, Blumberg N, McLeod SL, Liu J, Eikelboom JW, Guyatt GH. Transfusion of fresher versus older red blood cells in hospitalized patients: a systematic review and meta-analysis. Blood. 2016 Jan 28;127(4):400-10. 
  80. Chagla Z, Siegal D, El-Helou P, Lim W, Rudkowski J. Severe Acute Cytomegalovirus Infection Complicated by Disseminated Intravascular Coagulation and Pneumonitis in a Healthy Female. Canadian Journal of General Internal Medicine. 2016 Jan 19;10(4).  
  81. Marcucci M, Skjøth F, Lip GY, Iorio A. Larsen TB. A decisional model to individualize warfarin recommendations: Expected impact on treatment and outcome rates in real-world population with atrial fibrillation. Int J Cardiol. 2016 Jan;203:785-90. 
  82. E, Leblanc M, McFarlane P, Ribic CM. Serial Trough Anti-Xa Levels to Assess Low Molecular Weight Heparin Accumulation in Patients with Chronic Kidney Disease: Analysis of Crcl <30 Ml/Min from the Trivet Study. Blood. 2016;128:90.
  83. Fullerton HJ, Wintermark M, Hills NK, Dowling MM, Tan M, Rafay MF, Elkind MS, Barkovich AJ, Plumb PA, Benedict SL, Bernard TJ. Risk of Recurrent Arterial Ischemic Stroke in Childhood: A Prospective International Study. Stroke. 2016 Jan 1;47(1):53-9.  

2015

PLACEHOLDER TITLE
  1. Chai-Adisaksopha C, Hillis C, Monreal M, Witt DM, Crowther M. Thromboembolic events, recurrent bleeding and mortality after resuming anticoagulant following gastrointestinal bleeding. Thrombosis and haemostasis. 2015; 114(4):819-25.
  2. Hillis CM, Schimmer AD, Couban S, Crowther MA. The Canadian Choosing Wisely campaign: The Canadian Hematology Society’s top five tests and treatments. Ann Hematol. 2015; 94(4):541-5.
  3. Baumann Kreuziger L, Onwuemene O, Kolesar E, Crowther M, Lim W. Systematic review of anticoagulant treatment of catheter-related thrombosis. Thromb Res. 2015 Dec;136(6):1103-9
  4. Arnold DM. Bleeding complications in immune thrombocytopeniaHematology Am Soc Hematol Educ Program. 2015 Dec 5; 2015(1): 237-42.
  5. Matino D, Makris M, Dwan K, D’Amico R, Iorio A. Recombinant factor VIIa concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev. 2015 Dec 16;12.
  6. Warkentin TE. Heparin-induced thrombocytopeniaCurr Opin Crit Care 2015 Dec; 21 (6): 576-585. 
  7. Carcao MD, Iorio A. Individualizing factor replacement therapy in severe hemophilia. Semin Thromb Hemost. 2015 Nov;41(8):86471.
  8. Minuk L, Jackson S, Iorio A, Poon MC, Dilworth E, Brose K, Card R, Rizwan I, ChinYee B, Louzada M. Cardiovascular disease (CVD) in Canadians with haemophilia: Age Related CVD in Haemophilia Epidemiological Research (ARCHER study). Haemophilia. 2015 Nov;21 (6):73641.
  9. Strike KL, Iorio A, Jackson S, Lawson W, Scott L, Squire S, Chan AK. Point of care ultrasonography in haemophilia care: recommendations for training and competency evaluation. Haemophilia. 2015 Nov;21 (6):82831.
  10. Chai-Adisaksopha C, Hillis C, Thabane L, Iorio A. A systematic review of definitions and reporting of bleeding outcome measures in haemophilia. Haemophilia. 2015 Nov;21 (6):7315.
  11. Chai-Adisaksopa C, Hillis C, Isayama T, Lim W, Iorio A, Crowther M. Mortality outcomes in patients receiving direct oral anticoagulants: a systematic review and meta-analysis of randomized controlled trials. J Thromb Haemost. 2015 Nov;13(11):201220.
  12. Palareti L, Poti S, Cassis F, Emiliani F, Matino D, Iorio A. Shared topics on the experience of people with haemophilia living in the UK and the USA and the influence of individual and contextual variables: results from the HERO qualitative study. Int J Qual Stud Health Well-Being. 2015 Nov 16;10: 28915.
  13. Goldsmith R, Chan AK, Paes B, Bhatt MD, on behalf of the Thrombosis and Hemostasis in Newborns (THiN) Group. Feasibility and safety of enoxaparin whole milligram dosing in premature and term neonates.  Journal of Perinatology. 2015 Oct;35(10):852-854.  
  14. Nazi I, Arnold DM, Warkentin TE, Smith JW, Staibano P, Kelton JG. Distinguishing between anti-platelet factor 4/heparin antibodies that can and cannot cause heparin-induced thrombocytopeniaJ Thromb Haemost. 2015 Oct 13; 13(10): 1900-7.
  15. Matino D, Gargaro M, Santagostino E, Di Minno MN, Castaman G, Morfini M, Rocino A, Mancuso ME, Di Minno G, Coppola A, Talesa VN, Volpi C, Vacca C, Orabona C, Iannitti R, Mazzucconi MG, Santoro C, Tosti A, Chiappalupi S, Sorci G, Tagariello G, Belvini D, Radossi P, Landolfi R, Fuchs D, Boon L, Pirro M, Marchesini E, Grohmann U, Puccetti P, Iorio A, Fallarino F. IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII. J Clin Invest. 2015 Oct 1; 125(10):376681.
  16. Chai‐Adisaksopha C, Hillis C, Lim W, Boonyawat K, Moffat K, Crowther M. Hemodialysis for the treatment of dabigatran‐associated bleeding: a case report and systematic review. Journal of Thrombosis and Haemostasis. 2015 Oct 1; 13(10):1790-8.
  17. Turley E, McFarlane A, Halchuck L, Verhovsek MHemoglobin H identification by high-performance liquid chromatography in confirmed hemoglobin H diseaseInt J Lab Hematol. 2015 Oct; 37(5):668-72.
  18. Fischer K, Iorio A, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Gilman EA, Makris M; EUHASS Participants. Inhibitor development in nonsevere haemophilia across Europe. Thromb Haemost. 2015 Oct;114 (4):6705.
  19. Smythe MA, Forsyth LL, Warkentin TE, Smith MD, Sheppard JI, Shannon F. Progressive, fatal thrombosis associated with heparin-induced thrombocytopenia after cardiac surgery despite “therapeutic” anticoagulation with argatroban: potential role for PTT and ACT confoundingJ Cardiothorac Vasc Anesth. 2015 Oct; 29 (5): 1319-1321.
  20. Kwan C, Chan HHW, Chan AKC. Heterogeneity of information regarding inhibitors in the product monographs of antihemophilic factors in North America. Haemophilia. 2015 Sept;21(5):e448-51.   
  21. Neunert C, Arnold DM. Severe bleeding events in adults and children with primary immune thrombocytopenia: a systematic review: replyJ Thromb Haemost. 2015 Aug; 13(8): 1522-3.
  22. Neunert C, Noroozi N, Norman G, Buchanan GR, Goy J, Nazi I, Kelton JG, Arnold DM. Severe Bleeding Events in Adults and Children with Primary Immune Thrombocytopenia: A Systematic ReviewJ Thromb Haemost. 2015 Aug; 13(8):1522-3.
  23. Tassava T, Warkentin TE. Non-injection site necrotic skin lesions complicating postoperative heparin thromboprophylaxisAm J Hematol. 2015 Aug; 90 (8): 747-750.
  24. Warkentin TE. Ischemic limb gangrene with pulsesN Engl J Med. 2015 Aug 13; 373 (7): 642-655.
  25. Kumar R, Dawson JE, Chan AK, Forman‐Kay JD, Kahr WH, Williams S. c. 1058C> T variant in the SERPINC1 gene is pathogenic for antithrombin deficiency. British Journal of Haematology. 2015 Jul 1;170(1):123-5.
  26. Legault K, Hillis C, Crowther M, Schunemann H, Pai M. Systematic Review of Therapeutic Plasma Exchange for the Treatment of Catastrophic Antiphospholipid Antibody Syndrome. J Rheum. 2015 Jul; 42(7):1269-1269.
  27. Chan CM, Woods CJ, Warkentin TE, Sheppard JI, Shorr AF. The role for optical density in heparin-induced thrombocytopenia: a cohort studyChest. 2015 Jul 1; 148 (1): 55-61.
  28. Zeller MP, Al-Habsi KS, Golder M, Walsh GM, Sheffield WP. Plasma and plasma protein product transfusion: a Canadian blood services centre for innovation symposium. Transfusion Medicine Reviews. 2015 Jul 31; 29(3):181-94.
  29. Linkins L-A, Bates SM, Lee AYY, Heddle NM, Wang G, Warkentin TE. Combination of 4Ts score and PF4/H-PaGIA for diagnosis and management of heparin-induced thrombocytopenia: Prospective cohort study. Blood. 2015 Jul; 126(5):597-603.
  30. Warkentin TE, Cook RJ, Sarode R, Sloane DA, Crowther MA. Warfarin-induced venous limb ischemia/gangrene complicating cancer: a novel and clinically distinct syndromeBlood. 2015 Jul 23; 126 (4): 486-493.
  31. Romanov V, Marcucci M, Cheng J, Thabane L, Iorio A. Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor. Patient data meta-analysis of rAFH-PFM post authorization safety studies. Thromb Haemost. 2015 Jul; 114(1):5664.
  32. Nazi I, Arnold DM, Moore JC, Smith JW, Ivetic N, Horsewood P, Warkentin TE, Kelton JG. Pitfalls in the diagnosis of heparin-induced thrombocytopenia: a 6-year experience from a reference laboratoryAm J Hematol. 2015 Jul; 90 (7): 629-633.
  33. Barty RL, Gagliardi K, Owens W, Lauzon D, Scheuermann S, Liu Y, Wang G, Pai M, Heddle NM. A benchmarking program to reduce red blood cell outdating: Implementation, evaluation and a conceptual framework. Transfusion. 2015 Jul; 55(7):1621-7.
  34. Schulman S, Carrier M, Lee AYY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty RL, Wang G, Heddle NM, Douketis JD, on behalf of the Periop Dabigatran Study Group. Perioperative management of dabigatran: A prospective cohort study. Circulation. 2015 Jul; 132(3):167-173.
  35. Clark WF, Rock G, Barth D, Arnold DM, Webert KE, Yenson PR, Kelton JG, Li L, Foley SR, members of Canadian Apheresis Group. A phase-II sequential case-series study of all patients presenting to four plasma exchange centres with presumed relapsed/refractory thrombotic thrombocytopenic purpura treated with rituximab. Br J Haematol2015 Jul; 170(2): 208-17.
  36. Al-Shamsi HO, Al Farsi A, Anjum M, Shen H, Zbuk K, Cook RJ, Linkins LA, Major P. Thrombotic events in metastatic colorectal cancer patients treated with leucovorin, fluorouracil and irinotican (FOLFIRI) plus bevacizumab. Journal of gastrointestinal oncology. 2015 Jun;6(3):274.
  37. Delaney J, Schulman S, Salib M, Panju M, Pai M. Direct-acting oral anticoagulants in the real world: insights into appropriate prescribing and medication use. Journal of Thrombosis and Haemostasis. 2015 Jun;13:91.
  38. Warkentin TE, Arnold DM, Nazi I, Kelton JG. The platelet serotonin-release assay. Am J Hematol. 2015 Jun; 90(6):564-72.
  39. Hillis C, Crowther MA. Acute phase treatment of VTE: Anticoagulation, including non-vitamin K antagonist oral anticoagulants. Thromb Haemost. 2015 Jun; 113(6):1193-202.
  40. Goldman M, Lane D, Webert K, Fallis R. The prevalence of anti‐K in Canadian prenatal patients. Transfusion. 2015 Jun 1; 55(6pt2):1486-91.
  41. Klassen S, Wang M, Ross C, Verhovsek MRefractory mixed autoimmune hemolysis, thrombocytopenia, and thrombosis: a diagnostic puzzle. Ann Hematol Ann 2015 Jun; 94(6):1055-6.
  42. Berntorp E, Iorio A. Reflections on the FranceCoag report on inhibitory antibodies to factor VIII in patients with severe hemophilia A. Blood. 2015 Jun 11; 125(24):3816-7.
  43. Warkentin TE, Greinacher A, Bux J. The transfusion-related acute lung injury controversy: lessons from heparin-induced thrombocytopeniaTransfusion. 2015 May; 55 (5):1128-1134.
  44. Fischer K, Lassila R, Peyvandi F, Calizzani G, Gatt A, Lambert T, Windyga J, Iorio A, Gilman E, Makris M; EUHASS participants. Inhibitor development in haemophilia according to concentrate. Four-year results from the European HAemophilia Safety Surveillance (EUHASS) project. Thromb Haemost. 2015 May; 113(5):968-75.
  45. Marcucci M, Mancuso ME, Santagostino E, Kenet G, Elalfy M, Holzhauer S, Bidlingmaier C, Escuriola Ettingshausen C, Iorio A, Nowak-Göttl U. Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A. A patient-level meta-analysis. Thromb Haemost. 2015 May;113(5):958-67.
  46. Marcucci M, Iorio A, Douketis JD, Eichinger S, Tosetto A, Baglin T, Cushman M, Palareti G, Poli D, Tait RC, Kyrle PA. Risk of recurrence after a first unprovoked venous thromboembolism: external validation of the Vienna Prediction Model with pooled individual patient data. Thromb Haemost. 2015 May;13(5):77581.
  47. Rizwan I, Minuk L, Jackson S, Iorio A. Cardiovascular disease prevalence and relevance in haemophilia: a scoping review. Haemophilia. 2015 May; 21(3):e15666.
  48. Shih AW, Kolesar E, Ning S, Manning N, Arnold DM, Crowther MA. Evaluation of the appropriateness of frozen plasma usage after introduction of prothrombin complex concentrates: a retrospective study. Vox Sang. 2015 Apr; 108(3):274-80.
  49. Zeller M, Arnold DM. Risk infection to spare bleeding? The quandary of splenectomy for immune thrombocytopenia. Am J Hematology. 2015 Apr; 90(4):271-2.
  50. Arnold DM, Curtis BR, Bakchoul T, the Subcommittee of Platelet Immunology of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Recommendations for standardization of laboratory testing for drug-induced immune thrombocytopenia: communication from the SSC of the ISTHJ Thromb Haemost. 2015 Apr; 13(4):676-8.
  51. Warkentin TE. Scoring systems for heparin-induced thrombocytopenia (HIT): whither now? Thromb Haemost. 2015 Mar 3; 113 (3): 437-438.
  52. Morfini M, Marchesini E, Paladino E, Santoro C, Zanon E, Iorio A. Pharmacokinetics of plasma-derived vs. recombinant FVIII concentrates: a comparative study. Haemophilia. 2015 Mar; 21(2):204-9.
  53. Rivkin MJ, deVeber G, Ichord RN, Kirton A, Chan AK, Hovinga CA, Gill JC, Szabo A, Hill MD, Scholz K, Amlie-Lefond C. Thrombolysis in Pediatric Stroke Study. Stroke. 2015 Mar;46(3):880-5.   
  54. Rajpurkar M, Sharathkumar A, Williams S, Lau K, Ling SC, Chan AK. Recommendations for the assessment of non‐extremity venous thromboembolism outcomes: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2015 Mar 1;13(3):481-4
  55. Male C, Monagle P, Chan AK, Young G. Recommendations for the development of new anticoagulant drugs for pediatric use: communication from the SSC of the ISTH. Journal of Thrombosis and Haemostasis. 2015 Mar 1;13(3):481-4.
  56. Lim W, Vesely S, George JN. The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura: evidence-based focused review. Blood. 2015 Mar 5;125(10):1526-31.
  57. Lane SJ, Walker I, Chan AK, Heddle NM, Poon M-C, Minuk L, Jardine L, Arnold E, Sholapur NS, Webert KE. Treatment decision-making among Canadian youth with severe haemophilia: A qualitative approach. Haemophilia. 2015 Mar; 21(2):180-9.
  58. Heddle NM, Eikelboom J, Liu Y, Barty RL, Cook RJ. Exploratory studies on the age of transfused blood and in-hospital mortality in patients with cardiovascular diagnoses. Transfusion. 2015 Feb; 55(2):364-72.
  59. Chugh S, Darvish-Kazem S, Lim W, Crowther MA, Ghanima W, Wang G, Heddle NM, Kelton JG, Arnold DM. Rituximab plus standard of care for the treatment of primary immune thrombocytopenia: A systematic review and meta-analysis. The Lancet Haematology. 2015 Feb; 2(2):e75-e81.
  60. Shannon C Jackson, Ming Yang, Leonard Minuk, Michelle Scholzberg, Jean St-Louis, Alfonso Iorio, Robert Card and Man-Chiu Poon. Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Hematol. 2015 Feb 14;15:4.
  61. Arnold DM, Nazi I, Toltl L, Ross C, Ivetic N, Smith J, Yang L, Kelton, J. Antibody binding to megakaryocytes in vivo in patients with immune thrombocytopeniaEur J Hematology. 2015 Feb 13.
  62. Ichord RN, Benedict SL, Chan AK, Kirkham FJ, Nowak-Göttl U, Ashwal S, Ferriero D, Fullerton H, Ichord R, Kirkham F, Lynch JK. Paediatric cerebral sinovenous thrombosis: findings of the International Paediatric Stroke Study. Archives of disease in childhood. 2015 Feb 1;100(2):174-9.
  63. Lim W, Meade M, Lauzier F, Zarychanski R, Mehta S, Lamontagne F, Dodek P, McIntyre L, Hall R, Heels-Ansdell D, Fowler R, Pai M, Guyatt G, Crowther MA, Warkentin TE, Devereaux PJ, Walter SD, Muscedere J, Herridge M, Turgeon AF, Geerts W, Finfer S, Jacka M, Berwanger O, Ostermann O, Qushmaq I, Friedrich JO, Cook DJ; for the PROphylaxis for ThromboEmbolism in Critical Care Trial Investigators, the Canadian Critical Care Trials Group, and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Failure of anticoagulant thromboprophylaxis: risk factors in medical-surgical critically ill patientsCrit Care Med. 2015 Feb; 43 (2): 401-410.
  64. Warkentin TE. Heparin-induced thrombocytopenia in critically ill patientsSemin Thromb Haemost. 2015 Feb; 41 (1): 49-60.
  65. Jackson SC, Yang M, Minuk L, Sholzberg M, St-Louis J, Iorio A, Card R, Poon MC. Prophylaxis in older Canadian adults with hemophilia A: lessons and more questions. BMC Haematol. 2015 Feb 14; 15:4.
  66. Kaufman RM, Djulbegovic B, Gernsheimer T, Kleinman S, Tinmouth AT, Capocelli KE, Cipolle MD, Cohn CS, Fung MK, Grossman BJ, Mintz PD, Webert KE. Platelet transfusion: a Clinical Practice Guideline from the AABBPlatelet transfusion: a clinical practice guideline from the AABB. Annals of internal medicine. 2015 Feb 3; 162(3):205-13.
  67. Warkentin TE. 4Ts scoring with hemofiltration and hemodialysis clotting. J Clin Monit Comput. 2015 Feb; 29 (1): 7-9.
  68. Hsia CC, Liu Y, Eckert K, Monga N, Elia-Pacitti J, Heddle NM. Intravenous immunoglobulin (IVIg) utilization in immune thrombocytopenia (ITP) - A multi-center retrospective review. Drugs - Real World Outcomes. 2015 Jan; 2(1):35-42.
  69. Warkentin TE, Sheppard JI, Chu FV, Kapoor A, Crowther MA, Gangji A. Plasma exchange to remove HIT antibodies: dissociation between enzyme-immunoassay and platelet activation test reactivities. Blood. 2015 Jan 1; 125 (1): 195-198.
  70. Warkentin TE, Safyan EL, Linkins LA. Heparin-induced thrombocytopenia presenting as bilateral adrenal hemorrhages. N Engl J Med. 2015 Jan 29; 372 (5): 492-494.
  71. Selleng S, Selleng K, Friesecke S, Gründling M, Kuhn SO, Raschke R, Heidecke OJ, Hinz C, Hron G, Warkentin TE, Greinacher A. Prevalence and clinical implications of anti-PF4/heparin antibodies in intensive care patients: a prospective observational studyJ Thromb Thrombolysis. 2015 Jan; 39 (1): 60-67. doi: 10.1007/s11239-014-1105-2.
  72. Linkins LA, Warkentin TE. Rivaroxaban for treatment of HIT: a riveting first experienceThromb Res. 2015 Jan; 135 (1): 1-2.
  73. Shih A, Arnold DM. Plasma transfusion trials and tribulations. Transfusion. 2015 Jan; 55(1):14-6.
  74. McCarthy A, Moore A, Redhead L, McLaughlin P, Iorio A, Chowdary P. Development of haemophilic arthropathy of the ankle: results of a Delphi consensus survey on potential contributory factors. Haemophilia. 2015 Jan; 21(1):11623.
  75. Nugent D, Kalnins W, Querol F, Gregory M, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) study: treatment-related characteristics of the population. Haemophilia. 2015 Jan;21(1): e26-38.
  76. Kearon C, Spencer FA, O'Keeffe D, Lim W, et al. on behalf of the D-dimer Optimal Duration Study Investigators. D-dimer testing to select patients with a first unprovoked venous thromboembolism who can stop anticoagulant therapy: a cohort study. Ann Intern Med. 2015 Jan 6:162(1):27-34.

2014

PLACEHOLDER TITLE
  1. Kahn SR, Shapiro S, Wells PS, Lim W, et al. on behalf of the SOX trial investigators. Compression stockings to prevent post-thrombotic syndrome: a randomized placebo-controlled trial. Lancet. 2014; 383(9920):880-8.
  2. Arnold DM, Clare R, Salib M, Clayden R, Wang G, Nazi I, Kelton JG. The Mcmaster ITP Registry: Assessing the Prevalence, Clinical and Laboratory Features of Immune Thrombocytopenia. Blood. 2014 Dec 6;124(21):5008.
  3. Waiswa M, Seremba E, Ocama P, Ddungu H, Opio K, Okello C, O’Shea TVerhovsek M, Mutyabule R. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report. African Health Sciences. 2014; 14(4):1069-1073.
  4. Wong TE, Brandow AM, Lim W, Lottenberg R. Update on the use of hydroxyurea therapy in sickle cell disease. Blood. 2014 Dec 18;124(26):3850-7.
  5. Warkentin TE. Platelet microparticle generation assay for detection of HIT antibodies: advance, retreat, or too soon to tell? Thromb Res. 2014 Jan 5 pii: S0049-3848(14)00004-8.
  6. Warkentin TE, Sheppard JI, Manheim JC. HIT complicating fondaparinux prophylaxis: fondaparinux-dependent platelet activation as a marker for fondaparinux-induced HITThromb Haemost. 2014 Dec; 112 (6): 1319-1322.
  7. Mathew JG, Spyropoulos AC, Yusuf A, Vincent J, Eikelboom J, Shestakovska O, Fremes S, Noora J, Guo L, Peterson M, Pai M, Whitlock R. Efficacy and safety of early parenteral anticoagulation as a bridge to warfarin after mechanical valve replacement. Thromb Haemost. 2014 Dec 1; 112(6):1120-8.
  8. Wang KK, Charles C, Heddle NM, Arnold E, Molnar L, Arnold DM. Understanding why patients with immune thrombocytopenia are deeply divided on splenectomy. Health Expectations. 2014 Dec 1;17(6):809-17.
  9. Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji RA, Wells PS, Crowther MA. Design of the rivaroxaban for heparin-induced thrombocytopenia studyJ Thromb Thrombolysis. 2014 Nov; 38 (4): 485-492.
  10. Eikelboom JW, Warkentin TE. Immature platelet count: part of the cardiologist's complete blood count? J Am Coll Cardiol. 2014 Nov 18; 64 (20): 2130-2132.
  11. Zeller MP, Al-Habsi KS, Heddle NM. Prophylactic platelet transfusions: Should they be a treatment of the past? Curr Opin Hematol. 2014 Nov; 21(6):521-7.
  12. Athale A, Giguere A, Barbara A, Krassova S, Iorio A. Developing a two-sided intervention to facilitate shared decision-making in haemophilia: decision boxes  for clinicians and patient decision aids for patients. Haemophilia. 2014 Nov;20(6):800-6.
  13. Iorio A, Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L. Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM. Haemophilia. 2014 Nov;20(6):777-83. 
  14. Carcao MD, Iorio A. Individualizing Factor Replacement Therapy in Severe Hemophilia. Semin Thromb Hemost. 2015 Nov;41(8):864-71. 
  15. Mahan CE, Liu Y, Turpie AG, Vu JT, Heddle NM, Cook RJ, Dairkee U, Spyropoulos AC. External validation of a risk assessment model for venous thromboembolism in the hospitalized acutely-ill medical patient (VTE-VALOURR). Thromb Haemost. 2014 Oct; 112(4):692-9.
  16. Marcucci M, Lip GY, Nieuwlaat R, Pisters R, Crijns HJ, Iorio A. Stroke and bleeding risk co-distribution in real-world patients with atrial fibrillation: the Euro Heart Survey. Am J Med. 2014 Oct;127(10):979-86.e2. 
  17. Lieberman L, Liu Y, Portwine C, Barty RL, Heddle NM. An epidemiologic cohort study reviewing the practice of blood product transfusions among a population of pediatric oncology patients. Transfusion. 2014 Oct 1;54(10pt2):2736-44.
  18. Taneja R, Berry L, Pappu U, Stitt L, Sayal P, Allen P, Hoogendoorn H, Chan A. Protamine requirements in cardiac surgery: effect of changes in the heparin reference standard. Journal of cardiothoracic and vascular anesthesia. 2014 Oct 31;28(5):1227-32.
  19. Chai-Adisaksopha C, Crowther M, Isayama T, Lim W. The impact of bleeding complications in patients receiving target-specific oral anticoagulants: a systematic review and meta-analysis. Blood. 2014 Oct 9;124(15):2450-8.
  20. Lim W. Thrombotic risk in the antiphospholipid syndrome. Sem Thromb Haemost. 2014 Oct; 40(7):741-6.
  21. Kopolovic I, Warkentin TE. Progressive thrombocytopenia after cardiac surgery in a 67-year-old manCMAJ. 2014 Sep 2; 186 (12): 929-933.
  22. McCrindle BW, Li JS, Manlhiot C, Tweddell JS, Giglia TM, Massicotte MP, Monagle P, Krishnamurthy R, Mahaffey KW, Michelson AD, Verdun N. Challenges and Priorities for Research A Report From the National Heart, Lung, and Blood Institute (NHLBI)/National Institutes of Health (NIH) Working Group on Thrombosis in Pediatric Cardiology and Congenital Heart Disease. Circulation. 2014 Sep 30;130(14):1192-203.
  23. Ricci MJ, Medin JA, Foley RS. Advances in haplo-identical stem cell transplantation in adults with high-risk hematological malignancies. World journal of stem cells. 2014 Sep 26;6(4):380.
  24. Matino D, Iorio A. Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward. Haemophilia. 2014 Sep;20(5):604-6.
  25. Schulman S, Hwang HG, Eikelboom JW, Kearon C, Pai M, Delaney J. Loading dose versus maintenance dose of warfarin for re-initiation after invasive procedures: a randomized trial. J Thromb Haemost. 2014 Aug; 12(8):1254-9.
  26. Lau KK, Chan HH, Massicotte P, Chan AKC. Thrombotic complications of neonates and children with congenital nephrotic syndrome. Current Paediatric Reviews. 2014 Aug;10(3):169-76.
  27. Yudin J, Heddle NM. A 13-question approach to resolving serological discrepancies in the transfusion medicine laboratory. Laboratory Medicine. 2014 Aug 1;45(3):193-206.
  28. Santagostino E, Lentz SR, Busk AK, Regnault A, Iorio A. Assessment of the impact of treatment on quality of life of patients with haemophilia A at different ages: insights from two clinical trials on turoctocog alfa. Haemophilia. 2014 Jul; 20(4):527-34.
  29. Kumar R, Chan AK, Dawson JE, Forman‐Kay JD, Kahr WH, Williams S. Clinical presentation and molecular basis of congenital antithrombin deficiency in children: a cohort study. British Journal of Haematology. 2014 Jul 1;166(1):130-9.
  30. Firdouse M, Agarwal A, Chan AK, Mondal T.  Thrombosis and thromboembolic complications in Fontan patients: A literature review. Clinical and Applied Thrombosis/Hemostasis. 2014 Jul;20(5):484-92.
  31. Cassis FR, Buzzi A, Forsyth A, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) Study: influence of haemophilia on interpersonal relationships as reported by adults with haemophilia and parents of children with haemophilia. Haemophilia. 2014 Jul;20(4):e287-95.
  32. Traore AN, Chan AK, Webert KE, Heddle NM, Ritchie B, St-Louis J, Teitel J, Lillicrap D, Iorio A, Walker I. First analysis of 10-year trends in national factor concentrates usage in haemophilia: Data from CHARMS, the Canadian Hemophilia Assessment and Resource Management System. Haemophilia. 2014 Jul; 20(4):e251-9.
  33. Sheffield WP, Lambourne MD, Eltringham-Smith, LJ, Bhaka V, Arnold DM, Crowther MA. VT-S195A thrombin reduces the anticoagulant effects of dabigatran in vitro and in vivoJ Thromb Haemost. 2014 Jul;12(7):1110-5.
  34. Warkentin TE. Voting with your fondaparinux. Thromb Res. 2014 Jul; 134 (1): 3-4.
  35. Alak A, Jerzak KJ, Quirt JA, Lane SJ, Miller PA, Haider S, Arnold DM. How to succeed in research during medical training: a qualitative study. Clin Invest Med. 2014 Jun 1; 37(3):E117.
  36. Graf L, Moffat KA, Carlino SA, Chan AK, Iorio A, Giulivi A, Hayward CP. Evaluation of an automated method for measuring von Willebrand factor activity in clinical samples without ristocetin. International Journal of Laboratory Hematology. 2014 Jun 1;36(3):341-51.
  37. Crowther M, Cook D, Guyatt G, Zytaruk N, McDonald E, Williamson D, Albert M, Dodek P, Finfer S, Vallance S, Heels-Ansdell D,Warkentin TE. Heparin-induced thrombocytopenia in the critically ill: interpreting the 4Ts test in a randomized trial. Journal of critical care. 2014 Jun 30;29(3):470-e7.
  38. Warkentin TE. An Instrument-based Immunoassay with an Appropriate Normal Range: Minimizing HIT Overdiagnosis. Thrombosis research. 2014 Jun 1;133(6):961-2.
  39. Lozano M, Mahon A, van der Meer PF, Stanworth S, Cid J, Devine D, Fung MK, de la Salle B, Heddle NM, and on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Counting platelets at transfusion threshold levels: Impact on the decision to transfuse. A BEST Collaborative - UK NEQAS(H) International Exercise. Vox Sang. 2014 May; 106(4):330-336.
  40. Leung JM, Berry LR, Chan AK, Brash JL. Surface modification of polydimethylsiloxane with a covalent antithrombin-heparin complex to prevent thrombosis. Journal of Biomaterials Science, Polymer Edition. 2014 May 24;25(8):786-801.
  41. Westdorp H, Sköld AE, Snijer BA, Franik S, Mulder SF, Major PP, Foley R, Gerritsen WR, de Vries IJ. Immunotherapy for prostate cancer: lessons from responses to tumor-associated antigens. Front Immunol. 2014 May 6;5(1):1-5.  
  42. Jacskon SC, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, Poon MC. Patterns of tertiary prophylaxis in Canadian adults with severe and moderately severe haemophilia B. Haemophilia. 2014 May;20(3):e199-204. 
  43. Peyvandi F, Farrugia A, Iorio A, Key NS, Srivastava A. Joint WFH-ISTH session: issues in clinical trial design. Haemophilia. 2014 May;20 Suppl 4:137-44.
  44. Lee FMH, Chan AKC, Lau KK, Chan HH. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate:  A review of animal and human studies. Thrombosis Research. 2014 May;133(5):705-13.
  45. Shih A, Nazi I, Kelton JG, Arnold DM. Novel treatments for immune thrombocytopeniaPresse Med. 2014 Apr;43(4 Pt 2):e87-95.
  46. Odame JE, Chan AK, Wu JK, Breakey VR. Factor XIII deficiency management: A review of the literature. Blood Coagulation and Fibrinolysis. 2014 Apr;25(3):199-205.  
  47. Van Ommen CH, Chan AKC. Supportive care in pediatric cancer: The road to prevention of thrombosis. Seminars in Thrombosis and Hemostasis. 2014 Apr;40(3):371-81.  
  48. Matino D, Teitel J, Page D, Keepanassseril A, Iorio A, Walker I. The haemophilia certification system in Canada. Blood Transfus. 2014 Apr; 12 Suppl 3:e531-41.
  49. Shih AWY, McFarlane A, Verhovsek M. Haptoglobin Testing in Hemolysis: Measurement and Interpretation. American Journal of Hematology. 2014 Apr; 89(4):443-7.
  50. Athale AH, Marcucci M, Iorio A. Immune tolerance induction for treating inhibitors in people with congenital haemophilia A or B. Cochrane Database Syst Rev. 2014 Apr 24;4:CD010561
  51. Iorio A, Douketis JD. Ruling out DVT using the Wells rule and a D-dimer test. BMJ. 2014 Mar 10;348
  52. Park CK, Paes BA, Nagel K, Chan AK, Murthy P. Neonatal central venous catheter thrombosis: diagnosis, management and outcome. Blood Coagulation and Fibrinolysis. 2014 Mar;25(2):97-106.
  53. Matino D, Lillicrap D, Astermark J, Dolan G, Kessler C, Lambert T, Makris M,  O'Donnell J, Pipe S, Santagostino E, Saint-Remy JM, Schramm W, Iorio A. Switching clotting factor concentrates: considerations in estimating the risk of immunogenicity. Haemophilia. 2014 Mar;20(2):200-6. 
  54. Bakchoul T, Heckmann,, Arnold DM, Paes B, Bassler D, Theiele T, Smith JW, Volker K. Management of infants born with severe neonatal alloimmune thrombocytopenia:the role of platelet transfusions and intravenous immunoglobulin. Transfusion. 2014 Mar;54(3):640-5.
  55. Warkentin TE, Basciano PA, Knopman J, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: 2 new cases and a proposal for defining this disorderBlood. 2014; 123 (23): 3651-3654.
  56. Arnold E, Lane S, Webert KE, Chan A, Walker I, Tufts J, Rubin S, Poon MC, Heddle NM. What should men living with haemophilia need to know? The perspectives of Canadian men with haemophilia. Haemophilia. 2014 Mar; 20(2):219-225.
  57. Heddle NM, Lane SJ, Sholapur N, Arnold E, Newbold B, Eyles J, Webert KE. Implementation and public acceptability: lessons from food irradiation and how they might apply to pathogen reduction in blood productsVox Sang. 2014 Jul 1;107(1):50-9.
  58. Warkentin TE, Sheppard JI. Serological investigation of patients with a previous history of heparin-induced thrombocytopenia who are re-exposed to heparinBlood 2014 Apr 17; 123 (16): 2485-2493. Bakchoul T, Heckmann,, Arnold DM, Paes B, Bassler D, Theiele T, Smith JW, Volker K. Management of infants born with severe neonatal alloimmune thrombocytopenia. Transfusion. 2014 Mar; 54 (3): 640-5.
  59. Lieberman L, Bercovitz RS, Sholapur NS, Heddle NM, Stanworth SJ, Arnold DM. Platelet transfusions for critically ill patients with thrombocytopenia. Blood. 2014 Feb; 123(8):1146-1151.
  60. Warkentin TE. Anticoagulant failure in coagulopathic patients: PTT confounding and other pitfalls. Expert Opin Drug Saf. 2014 Jan; 13(1):25-43.
  61. Donadini MP, Ageno W, Antonucci E, Cosmi B, Kovacs MJ, Le Gal G, Ockelford P, Poli D, Prandoni P, Rodger M, Saccullo G, Siragusa S, Young L, Bonzini M, Caprioli M, Dentali F, Iorio A, Douketis JD. Prognostic significance of residual venous obstruction in patients with treated unprovoked deep vein thrombosis: a patient-level meta-analysis. Thromb Haemost. 2014 Jan; 111(1):172-9.
  62. Forsyth AL, Gregory M, Nugent D, Garrido C, Pilgaard T, Cooper DL, Iorio A. Haemophilia Experiences, Results and Opportunities (HERO) Study: survey methodology and population demographics. Haemophilia. 2014 Jan;20(1):44-51.

2013

PLACEHOLDER TITLE
  1. Arnold DM. Positioning new treatments in the management of immune thrombocytopeniaPediatr Blood Cancer 2013; 60 Suppl 1:S19-22.
  2. Páez A, Esita J, Newbold KB, Heddle NM, Blake JT. Exploring resource allocation and alternate clinic accessibility landscapes for improved blood donor turnoutAppl Geogr. 2013 Dec; 45:89-97.
  3. Lauzier F, Arnold DM, Rabbat C, Heels-Ansdell D, Zarychanski R, Dodek P, Ashley BJ, Albert M, Khwaja K, Ostermann M, Skrobik Y, Fowler R, McIntyre L, Nates JL, Karachi T, Lopes RD, Zytaruk N, Finfer S, Crowther M, Cook D. Risk factors and impact of major bleeding in critically ill patients receiving heparin thromboprophylaxis. Intensive Care Med. 2013 Dec; 39(12):2135-43.
  4. Ghadaki B, Nazi I, Kelton JG, Arnold DM. Sustained remissions of immune thrombocytopenia associated with the use of thrombopoietin receptor agonists. Transfusion. 2013 Nov 1;53(11):2807-12.
  5. Dasgupta A, Radford K, Arnold DM, Thabane L, Nair P. The effects of rituximab on serum igE and BAFFAllergy Asthma Clin Immunology. 2013 Oct 3; 9:39. doi: 10.1186/1710-1492-9-39.
  6. Williamson D, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, Crowther MA, Warkentin TW, Dodek P, Cade J, Lesur O, Lim W, Fowler R, Lamontagne F, Langevin S, Freitag A, Muscedere J, Friedrich J, Geerts W, Burry L, Alhashemi J, Cook D; PROTECT collaborators; Canadian Critical Care Trials Group; Australian and New Zealand Intensive Care Society Clinical Trials Group. Thrombocytopenia in critically ill patients receiving thromboprophylaxis: Frequency, risk factors and outcomesChest. 2013 Oct; 144(4):1207-15. doi: 10.1378/chest.13-0121.
  7. Raschke RA, Curry SC, Warkentin TE, Gerkin RD. Improving clinical interpretation of the anti-platelet factor 4/heparin enzyme-linked immunosorbent assay for the diagnosis of heparin-induced thrombocytopenia through the use of receiver operating characteristic analysis, statum-specific likelihood ratios, and Bayes theoremChest. 2013 Oct 1; 144(4):1269-1275.
  8. Tinmouth A, Thompson T, Arnold DM, Callum JL, Gagliardi K, Lauzon D, Owens W, Pinkerton P. Utilization of frozen plasma in Ontario: a province wide audit reveals a high rate of inappropriate transfusions. Transfusion. 2013 Oct 1;53(10):2222-9.
  9. Williamson DR, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Zarychanski R, Crowther M, Warkentin TE, Dodek P, Cade J, Lesur O, Lim W, Fowler R, Lamontagne F, Langevin S, Freitag A, Muscedere J, Friedrich JO, Geerts W, Burry L, Alhashemi J, Cook D. Thrombocytopenia in the critically ill: frequency, risk factors and outcomesChest. 2013 Oct 1; 144(4):1207-1215.
  10. Nazi I, Kelton JG, Larché M, Snider DP, Heddle NM, Crowther MA, Cook RJ, Tinmouth AT, Mangel J, Arnold DM. The effect of rituximab on vaccine responses in patients with immune thrombocytopenia. Blood. 2013 Sep; 122(11):1946-53.
  11. Sholapur NS, Barty R, Wang G, Almonte T, Heddle NM. A survey of patients with haemophilia to understand how they track product used at home. Haemophilia. 2013 Sep; 19(5):e289-95. doi: 10.1111/hae.12170.
  12. Pai M, Chan AK, Barr R. How I manage heavy menstrual bleedingBr J Haem. 2013 Sep; 162(6):721-9.
  13. Warkentin TE, Sheppard JI, Heels-Ansdell D, Marshall JC, McIntyre L, Rocha MG, Mehta S, Davies AR, Bersten AD, Crozier TM, Ernest D, Vlahakis NE, Hall RI, Wood GG, Poirier G, Crowther MA, Cook DJ. Heparin-induced thrombocytopenia in medical surgical critical illnessChest. 2013 Sep; 144(3):848-858.
  14. Eder AF, Webert KE, Arnold DM, Lui Y, Carruthers J, Arnold E, Heddle NM. Continuing medical education program in transfusion. Transfusion. 2013 Aug; 53(8):1687.
  15. Cook RJ, Heddle NM. Clinical trials evaluating pathogen reduced platelet products: Methodological issues and recommendationsTransfusion. 2013 Aug; 53(8):1843-55.
  16. Estcourt LJ, Heddle NM, Kaufman R, McCullough J, Murphy MF, Slichter S, Wood EM, Stanworth SJ, Biomedical Excellence for Safer Transfusion (BEST) Collaborative. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusionsTransfusion. 2013 Jul; 53(7):1531-43.
  17. Lane S, Arnold E, Webert KE, Chan A, Walker I, Heddle NM. What should men living with severe haemophilia need to know? The perspectives of Canadian haemophilia health care providersHaemophilia. 2013 Jul; 19(4):503-10.
  18. Arnold, DM. A platelet cover-upBlood. 2013 Jul 18; 122(3):307-9. doi:10.1182/blood-2013-05-501213.
  19. Arnold DM, Nazi I, Warkentin TW, Smith JW, Toltl LJ, George JN, Kelton JG. Approach to the diagnosis and management of drug-induced immune thrombocytopeniaTransfus Med Rev. 2013 Jul; 27(3):137-45.
  20. Nazi I, Arnold DM, Smith JW, Horsewood P, Moore JC, Warkentin TE, Crowther MA, Kelton JG. FcyRlla proteolysis as a diagnostic biomarker for heparin-induced thrombocytopeniaJ Throm Haemost. 2013 Jun; 11(6):1146-53.
  21. Dasgupta A, Sanaee MS, Bauer CM, Botelho FM, Arnold DM, Stampfli MR, Nair P. Asthma associated with incontinentia pigmenti and fanconi anemia: Variable airflow limitation without cellular bronchitisChest. 2013 Mar 1; 143(3): 856-8.
  22. Arnold DM, Lauzier F, Rabbat C, Zytaruk N, Barlow Cash B, Clarke F, Heels-Ansdell D, Guyatt G, Walter SD, Davies A, Cook DJ;  For the PROTECT Investigators, on behalf of the Canadian Critical Care Trials Group and the Australian and New Zealand Intensive Care Society Clinical Trials Group. Adjudication of bleeding outcomes in an international thromboprophylaxis trial in critical illnessThromb Res. 2013 Mar; 131(3):204-9.
  23. Kelton JG, Arnold DM, Bates SM. Non-heparin anticoagulants for heparin-induced thrombocytopeniaN Engl J Med. 2013 Feb 21; 368(8): 737-44.
  24. Mahabir VK, Ross C, Popovic S, Sur ML, Bourgeois J, Lim W, George JN, Wang G, Cook RJ, Toltl LJ, Nazi I, Kelton JG, Arnold DM. A blinded study of bone marrow examinations in patients with primary immune thrombocytopeniaEur J Haematol. 2013 Feb; 90(2):121-6.
  25. Warkentin TE, Sheppard JI, Sun JCJ, Jung H, Eikelboom JW. Anti-PF4/heparin antibodies and venous graft occlusion in post coronary artery bypass surgery patients randomized to postoperative unfractionated heparin or fondaparinux prophylaxisJ Thromb Haemost. 2013 Feb; 11(2):253-260.
  26. Thiele T, Heddle NM, Greinacher A. Donor exposures in recipients of pooled platelet concentratesN Engl J Med. 2013 Jan 31; 368(5):487-9.
  27. Arnold DM, Kukaswadia S, Nazi I, Goldberg A, Dewar L, Smith JW, Warkentin TE, Kelton JG. A systematic evaluation of laboratory testing for drug-induced immune thrombocytopeniaJ Thromb Haemost. 2013 Jan; 11(1):169-76. doi: 10.1111/jth.12052.
  28. Pai M, Lloyd NS, Cheng J, Thabane L, Spencer FA, Cook DJ, Haynes RB, Schünemann HJ, Douketis JD. Strategies to Enhance Venous Thromboprophylaxis in Hospitalized Medical Patients (SENTRY): A Pilot Cluster Randomized TrialImplement Sci. 2013 Jan; 8:1.
  29. Bakchoul T, Zöllner H, Amiral J, Panzer S, Selleng S, Kohlmann T, Brandt S, Delcea M, Warkentin TE, Sachs UJ, Greinacher A. Anti-protamine–heparin antibodies: incidence, clinical relevance and pathogenesisBlood. 2013; 121(15):2821-2827.
  30. Zimrin AB, Warkentin TE. Transient pseudothrombocytopenia associated with immune heparin-induced thrombocytopenia complicated by pulmonary embolismThromb Haemost. 2013; 109(5):971-973.

2012

PLACEHOLDER TITLE
  1. Toltl LJ, Arnold DM. Leaving nothing to chance: How to randomize a clinical trial. Transfusion. 2012 Dec; 52(12):2513-5.
  2. Bhagirath VC, Kelton JG, Moore J, Arnold DM. Rituximab maintenance for relapsed refractory thrombotic thrombocytopenic purpuraTransfusion. 2012 Dec; 52(12):2517-23.
  3. Webert KE, Arnold DM, Lui Y, Carruthers J, Arnold E, Heddle NM. A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia. Transfusion. 2012 Nov; 52(11):2466-74.
  4. Eder AF, Webert KE, Arnold DM, Lui Y, Carruthers J, Arnold E, Heddle NM.  Continuing medical education program in transfusion. Transfusion. 2012 Nov; 52(11):2465.
  5. Cuker A, Gimotty PA, Crowther MA, Warkentin TE. Predictive value of the 4Ts scoring system for heparin-induced thrombocytopenia: a systematic review and meta-analysisBlood. 2012 Nov 15; 120(20):4160-4167.
  6. Warkentin TE. Aspirin for dual prevention of venous and arterial thrombosisN Engl J Med 2012 Nov 22; 367(21):2039-2041.
  7. Apelseth TO, Molnar L, Arnold E, Heddle NM. Benchmarking: Applications to Transfusion Medicine. Transfus Med Rev. 2012 Oct; 26(4):321-322.
  8. Josephson CD, Glynn SA, Kleinman SH, Blajchman MA; State-of-the-Science Symposium Transfusion Medicine Committee. A multidisciplinary “think tank”: The top 10 clinical trial opportunities in transfusion medicine from the National Heart, Lung, and Blood Institute-sponsored 2009 state-of-the-science symposiumTransfusion. 2011 Apr; 51(4):828-41.
  9. Arnold DM. Platelet count or bleeding as the outcome in ITP trials? Am J Hematol. 2012 Oct; 87(10):945-6.
  10. Hayward CP, Webert KE. Expert approaches to common bleeding and thrombotic problems - Part ISemin Thromb Hemost. 2012 Oct; 38(7):641-4.
  11. Warkentin TE. Heparin-induced thrombocytopenia in the ICU: a transatlantic perspectiveChest. 2012 Oct 1; 142(4):815-816.
  12. Webert KE.  Acquired Hemophilia ASemin Thromb Hemost. 2012 Oct; 38(7):735-741.
  13. Almonte T, Decker K, Seroski W, Walker I, Webert KE, Bos C, Strike K, Waterhouse L, Goldsmith R, Chan AK. The importance of haemophilia treatment centre administrators in patient caseHaemophilia. 2012 Sep; 18(5):e366-367.
  14. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in murine coagulopathy induced by warfarin, but not in that induced by dabigatran etexilateJ Thromb Haemost. 2012 Sep; 10(9):1830-40.
  15. Arnold DM. Immune thrombocytopenia: Getting back to basicsAm J Hematol. 2012 Sep; 87(9):841-2.
  16. Milkovic JS, Warkentin TE, Richardson RMA, Prebtani APH. Fatal hyponatremia associated with preoperative desmopressin for bleeding disorder. J Anesthesiol Clin Sci. 2012; 1: 1: available as open access article [doi: hppt://dx.doi.org/10.7243/2049-9752-1-11] at http://www.hoajonline.com/journals/jacs/content/pdf/11.pdf. [published 15 Sep 2012]
  17. Heddle NM, Fung M, Hervig T, Szczepiorkowski ZM, Torretta L, Arnold E, Lane S, Murphy MF; for the BEST Collaborative.Challenges and opportunities to prevent transfusion errors: A Qualitative Evaluation for Safer Transfusion (QUEST). Transfusion. 2012 Aug; 52(8):1687-95.
  18. Warkentin TE, Chakraborty AK, Sheppard JI, Griffin DK. The serological profile of fondaparinux-associated heparin-induced thrombocytopenia syndromeThromb Haemost. 2012 Aug; 108(2):394-396.
  19. Siegal DM, Cook RJ, Warkentin TE. Acute hepatic necrosis and ischemic limb necrosisN Engl J Med. 2012 Aug 30; 367(9):879-881.
  20. Kelton JG, Warkentin TE, Moore JC, Arnold DM, Nazi I, Arepally GM, Roach JM Fier I. A prospective study measuring the development of antibodies against platelet factor 4 in healthy males following exposure to heparinsJ Thromb Haemost. 2012 Jul; 10(7):1446-9.
  21. Heddle NM, Cook RJ, Arnold DM, Crowther MA, Warkentin TE, Webert KE, Hirsh J, Barty RL, Liu Y, Lester C, Eikelboom JW. The effect of blood storage duration on in-hospital mortality: A randomized controlled pilot feasibility trial. Transfusion. 2012 Jun; 52(6):1203-12.
  22. Blajchman MA, Carson JL, Eikelboom JW, Heddle NM, Lacroix J, Lauer MS, Platt R, Tilley B, Triulzi D, Vickers AJ, Yusuf S, Glynn S, Mondoro TH, Wagner E. The role of comparative effectiveness research in transfusion medicine clinical trials: proceedings of a National Heart, Lung, and Blood Institute workshop. Transfusion. 2012 Jun; 52(6):1363-78.
  23. Ditomasso J, Liu Y, Heddle NM. The Canadian Transfusion Surveillance System: What is it and how can the data be used? Transfus Apher Sci. 2012 Jun; 46(3):329-35.
  24. Meyer E, Delaney M, Lin Y, Morris A, Pavenski K, Tinmouth A, Murphy M, Slichter SJ, Heddle NM, Dumont LJ. A reporting guideline for clinical platelet transfusion studies from the BEST CollaborativeTransfusion. 2013 Jun; 53(6):1328-34.
  25. Heddle HM, Cook RJ, Arnold DM, Crowther MA, Warkentin TE, Webert KE, Hirsh J, Barty RL, Liu Y, Lester C, Eikelboom JW. The effect of blood storage duration on in-hospital mortality: A randomized controlled pilot feasibility trialTransfusion. 2012 Jun; 52(6):1203-12.
  26. Ghanny S, Warkentin TE, Crowther MA. Reversing anticoagulant therapyCurr Drug Discov Technol 2012 Jun 1; 9(2):143-149.
  27. Warkentin TE, Eikelboom JW. Old blood bad? Either the biggest issue in transfusion medicine or a noneventTransfusion. 2012 Jun; 52(6):1165-1167. [Editorial on: Wang D, Sun J, Solomon SB, Klein HG, Natanson C. Transfusion of older stored blood and risk of death: a meta-analysis. Transfusion. 2012 Jun; 52(6):1184-1195.]
  28. Hudoba M, Dalal B, Warkentin TE, Pal J, Chipperfield K, Pi D, Tsang P, Coupland R, Carter CJ. Toward better utilization of laboratory resources: the impact of a mandatory 4Ts pretest clinical assessment form on the diagnosis of heparin-induced thrombocytopenia. BC Medical Journal. 2012 Jun; 54(5):244-247.
  29. Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A, Heddle NM. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Db Syst Rev. 2012 May 16; 5:CD004269. doi: 10.1002/14651858.CD004269.pub3.
  30. Gauvin F, Robillard P, Hume H, Grenier D, Whyte RK, Webert KE, Fergusson D, Lau W, Froese N, Delage G. Transfusion-related acute lung injury in the Canadian paediatric populationPaediatr Child Health. 2012 May; 17(5):235-9.
  31. Webert KE, Rivard GE, Teitel J, Carcao M, Lillicrap D, St-Louis J, Walker IR. Low prevalence of inhibitor antibodies in the Canadian haemophilia populationHaemophilia. 2012 May; 18(3):e254-9.
  32. Warkentin TE. HIT lights: a career perspective on heparin-induced thrombocytopeniaAm J Hematol. 2012 May; 87(Suppl. 1): S92-S99.
  33. Warkentin TE, Moore JC, Vogel S, Sheppard JI, Warkentin NI, Eikelboom JW. The serological profile of early-onset and persisting post-cardiac surgery thrombocytopenia complicated by “true” heparin-induced thrombocytopeniaThromb Haemost. 2012 May; 107(5):998-1000.
  34. Arnold DM, Santoso S, Greinacher A, on behalf of the Platelet Immunology Scientific Subcommittee of ISTH.  Recommendations for the implementation of platelet autoantibody testing in clinical trials of immune thrombocytopeniaJ Thromb Haemost. 2012 Apr; 10 (4):695-7.
  35. Warkentin TE. Hemodialysis-associated acute systemic reactions and heparin-induced thrombocytopeniaThromb Res 2012 Apr; 129(4):405-406. [Editorial commentary on: Matsuo T, Wanaka K, Miyasita K, Prechel M, Walenga JM. Clinical evaluation of acute systemic reaction and detection of IgG antibodies against PF4/heparin complexes in hemodialysis patients. Thromb Res. 2012 Apr; 129(4):474-478.]
  36. Cimaroli K, Páez A, Newbold KB, Heddle NM. Individual and contextual determinants of blood donation frequency with a focus on clinic accessibility: A case study of Toronto, Canada. Health Place. 2012 Mar; 18(2):424-33.
  37. Thiele T, Kellner S, Hron G, Wasner C, Nauck M, Zimmermann K, Wessel A, Warkentin TE, Greinacher A, Selleng K. Storage of thawed plasma for a liquid plasma bank: impact of temperature and methylene blue pathogen inactivationTransfusion. 2012 Mar; 52(3):529-536.
  38. Warkentin TE, Margetts P, Connolly SJ, Lamy A, Ricci C, Eikelboom JW. Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated post cardiac surgery bleedingBlood. 2012 Mar 1; 119 (19): 2172-2174, 2012.
  39. Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, Liu Y, Cook RJ, McLeod A, MacEachern JA, Mangel J, Anderson D, Vickars L, Tinmouth A, Schuh AC, Kelton JG. A pilot randomized trial of adjuvant rituximab or placebo for non-splenectomized patients with immune thrombocytopeniaBlood. 2012 Feb 9; 119(6):1356-62.
  40. Drackley A, Newbold KB, Paez A, Heddle NM. Forecasting Ontario’s blood supply and demand. Transfusion 2012 Feb; 52(2):366-374.
  41. Arnold DM, Heddle NM, Carruthers J, Cook DJ, Crowther MA, Meyer RM, Liu Y, Cook RJ, McLeod A, MacEachern JA, Mangel J, Anderson D, Vickars L, Tinmouth A, Schuh AC, Kelton JG. A pilot randomized trial of adjuvant rituximab or placebo for nonsplenectomized patients with immune thrombocytopenia. Blood. 2012 Feb 9; 119(6):1356-62.
  42. Duffett M, Burns KE, Adhikari NK, Arnold DM, Lauzier F, Kho ME, Meade MO, Hayani O, Koo K, Choong K, Lamontagne F, Zhou Q, Cook DJ. Quality of reporting of surveys in critical care journals: A methodologic reviewCrit Care Med. 2012 Feb; 40(2):441-9.
  43. Warkentin TE. HIT treatment easier, HIT prevention harderBlood 2012 Feb 2; 119(5):1099-1100. [Inside Blood Commentary on: Krauel K, Hackbarth C, Fürll B, Greinacher A. Heparin-induced thrombocytopenia: in-vitro studies on the interaction of dabigatran, rivaroxaban, and low-sulfated heparin, with platelet factor 4 and anti-PF4/heparin antibodies. Blood. 2012 Feb 2; 119(5):1248-1255.]
  44. Iskedjian M, Tinmouth AT, Arnold DM, Deuson R, Isitt JJ, Mikhael J. Elicitation of utility scores in Canada for immune thrombocytopenia treated with romiplostim or watch and rescueJ Med Econ. Jan 2012; 15(2):313-31.
  45. Lloyd NS, Douketis JD, Cheng J, Schünemann HJ, Cook DJ, Thabane L, Pai M, Spencer FA, Haynes RB. Barriers and potential solutions toward optimal prophylaxis against deep vein thrombosis for hospitalized medical patients: A survey of healthcare professionals. J Hosp Med. 2012 Jan; 7(1):28-34.
  46. Pai M, Warkentin TE, Cook RJ. Intraoperative anticoagulation and limb amputations in patients with immune heparin-induced thrombocytopenia who require vascular surgeryJ Thromb Haemost. 2012 Jan; 10(1):148-50.
  47. Yusuf AM, Warkentin TE, Arsenault KA, Whitlock R, Eikelboom JW. Prognostic importance of preoperative anti-PF4/heparin antibodies in patients undergoing cardiac surgery. A systematic review. Thromb Haemost. 2012 Jan; 107(1):8-14.
  48. Warkentin TE. Optical densities reduce odds of heparin-induced thrombocytopenia over-diagnosisAm J Med 2012 Jan; 125 (1): 3-4. [doi: 10.1016/j.amjmed.2011.10.001] [PMID: 22195526] [Editorial commentary on: Baroletti S, Hurwitz S, Conti NAS, Fanikos J, Piazza G, Goldhaber SZ. Thrombosis in suspected heparin-induced thrombocytopenia occurs more often with high antibody levels. Am J Med. 2012 Jan 125(1):44-49.
  49. Pai MCrowther MA. Neutralization of Heparin ActivityHandb Exp Pharmacol. 2012; (207):265-77.

Published Abstracts

2018

PLACEHOLDER TITLE

 

  1. Douketis J, Spyropoulos AC, Duncan JM, Carrier M, Le Gal G, Tafur AJ, Vanassche P, Shivakumar SP, Gross PL, Ying Lee, AY, Yeo E, Solymoss S, Kassis J, Le Templie G, Kowalski S, Blostein M, Shah V, MacKay E, Wu CM, Clark N, Bates SM, Spencer F, Arnaoutoglou E, Coppens M, Arnold DM, Caprini JA, Moffat K, Summer S, Schulman S. Perioperative Anticoagulant Use for Surgery Evaluation (PAUSE) study: A perioperative management plan for patients with atrial fibrillation who are receiving a direct oral anticoagulant. Late-Breaking Abstract (LBA-5) presented at at ASH Annual Meeting, San Diego, CA, 2018.
  2. Mithoowani S, Cervi A, Shah N, Ejaz R, Barty R, Li N, Nazy I, Arnold DM. Urgent Management of Bleeding in Immune Thrombocytopenia: Towards a Standardized Protocol in the Emergency Department. ASH 60th Annual Meeting and Exposition, San Diego, CA, 2018.
  3. Cooper N, Kruse A, Kruse C, Watson S, Morgan M, Bussel J, Ghanima W, Arnold DM, Santoro C, Hou M, Tomiyama Y, Laborde S, Lovrencic B, Waller J, Bailey T, Taylor-Stokes G, Stankovic M, Provan D. Results from the ITP World Impact Survey (I-WISh): Patients with immune thrombocytopenia (ITP) experience impaired quality of life (QoL) regarding daily activities, social interactions, emotional well-being and working lives. Poster (#4804) presented at ASH Annual Meeting, San Diego CA, 2018.
  4. Arnold DM, Kelton JG, Neunert C, Bakchoul T. What's Hot in Immune Thrombocytopenia Purpura (ITP)? ASH Annual Meeting, San Diego, CA, 2018.
  5. Duliege A-M, Arnold DM, Boccia R, Boxer MA, Cooper N, Hill Q, Liles D, Sholzberg M, Zayed H, Tong S, Bussel J on behalf of the FIT investigators. Two-year safety and efficacy outcomes with Fostamatinib in adult patients with immune thrombocytopenia (ITP): Open-label extension to the phase 3 trial program. Oral presentation (#736) at ASH Annual Meeting, San Diego, CA, 2018.
  6. Kruse C, Kruse A, Watson S, Morgan M, Cooper N, Ghanima W, Provan D, Arnold DM, Santoro C, Hou M, Tomiyama Y, Laborde S, Lovrencic B, Waller J, Taylor-Stokes G, Bailey T, Stankovic M, Bussel J. Patients with immune thrombocytopenia (ITP) frequently experience severe fatigue but it is under-recognized by physicians: Results from the ITP World Impact Survey (I-WISh). Poster (#2273) presented at ASH Annual Meeting, San Diego CA, 2018.
  7. Newland A, Bussel J, Bird R, Arnold DM, Kessler C, Mayer J, Tejeda Romero M, Janssens A, Wang K, Eisen M. Predictors of remission in adults with immune thrombocytopenia (ITP) treated with Romiplostim. Oral presentation (#735) at ASH Annual Meeting, San Diego, CA, 2018.
  8. Cooper N, Ghanima W, Provan D, Arnold DM, Michel M, Santoro C, Kruse A, Kruse C, Watson S, Morgan M, Hou M, Tomiyama Y, Laborde S, Lovrencic B, Waller J, Taylor-Stokes G, Judge D, Stankovic M, Bussel J. Immune thrombocytopenia (ITP) is associated with a high disease burden and has a negative impact on patient-reported quality of life and productivity: Results from the ITP World Impact Survey (I-WISh). Poster presented at the European Congress on Thrombosis and Haemostasis (ECTH), Marseille, France, 2018. ECTH Abstract Book 2018; Platelets 1; PS 9.1; Board No. 49:119.
  9. Zeller MP. Development of a 'Gold Standard' Informed Consent Narrative for Blood Transfusion. AABB Annual Meeting, Boston, MA, 2018.
  10. Ning S, Liu Y, Li N, Barty RL, Acker JP, Cook RJ, Zeller MP, Arnold DM, Heddle NM. Exploring the potential harm of short-term blood storage on patients undergoing cardiovascular surgery. AABB Annual Meeting, Boston, MA, Oct 13-16, 2018. Transfusion 2018; 58(Issue S2):209A-BBC45.
  11. Zeller M, Rochwerg B, Hillis C, Runciman RJR, Lane S, Jamula E, Li N, Arnold DM, Heddle NM. Sex-mismatched red blood cell transfusions and mortality: A systematic review and meta-analysis. AABB Annual Meeting, Boston, MA, Oct 13-16, 2018. Transfusion 2018; 58(Issue S2):126A-TS85.
  12. Vrbensky JR, Nazy I, Ivetic N, Clare R, Jaffer AM, Kelton JG, Arnold DM. Increased cytotoxic potential of CD8 cells in patients with immune thrombocytopenia. ISTH Annual SSC Meeting, Dublin, Ireland, 2018. J Thromb Haemost 2018; 2(Issue S1):PB112. 
  13. Heddle NM, Cook R, Liu Y, Zeller M, Barty RL, Acker J, Eikelboom J, Arnold DM. The association between donor sex and age and mortality in blood transfusion recipients: An exploratory analysis. ISBT International Congress 2018, Toronto, ON, 2018. Vox Sang 2018; 113(S1):5C-S39-04.
  14. Ning S, Morin P, Barty RL, Liu Y, Li N, Elahie A, Zeller M, Heddle NM. The frequency of red cell transfusions in Kell alloimmunized females of current and future child bearing potential. ISBT International Congress 2018, Toronto, ON, 2018. Vox Sang 2018; 113(S1):P-757.
  15. Shih AW, Heddle NM, Barty RL, Li N, Acker J, Q MIP Investigators on behalf of the BEST Collaborative. Processing methods and quality markers in the production of red blood cell units. ISBT International Congress 2018, Toronto, ON, 2018. Vox Sang 2018; 113(S1):5A-S34-02.
  16. Bussel JB, Arnold DM, Cooper N, Abdallah A, Boxer M, Liles DK, Ghanima W, McCrae K, Zayed H, Tong S, Cadieux B, Duliege A-M. Two placebo-controlled phase 3 studies of fostamatinib, an oral spleen tyrosine kinase (Syk) inhibitor, for the treatment of persistent/chronic immune thrombocytopenia (ITP) in adults: Analysis of platelet response by prior ITP therapies. ASCO Annual Meeting, Chicago, IL, 2018. J Clin Oncol 2018; 36(18)(suppl; abst e15146). 
  17. Rochwerg B, D'Aragon F, Zeller M, Millen T, Austin P, Masse MH, Mehta S, Lamontagne F, Meade MO, Guyatt G, Cook DJ, Canadian Critical Care Trials Group. Fluids in Septic Shock (FISSH): A Pilot Randomized Controlled Trial. ATS Annual Conference, San Diego, CA, 2018.
  18. Noone, C. Chai-Adisaksopha, R. Curtis, N. Frick, M. Nichol, B. O'Mahony, D. Page, J. Stonebraker, A. Iorio, M.W. Skinner on behalf of Patient Reported Outcomes and Experiences (PROBE) Investigator Group. Haemophilia 2018, 24 (Suppl 1); OR07.   
  19. Beslow LA, Dowling MM, Hassanein SM, Zafeiriou D, Sun LR, Kopyta IA, Chan AK, Biller J, Lynch JK, Grabowski EF, Titomanlio L, Kolk A, Abdalla AA, Mackay MT, deVeber G. Abstract 15: Mortality After Pediatric Arterial Ischemic Stroke: Results From the International Paediatric Stroke Study. International Stroke Conference, Los Angeles, CA, 2018

2017

PLACEHOLDER TITLE
  1. Heddle NM, Cook RJ, Lee K-A, Arnold DM, Crowther M, Devereaux PJ, Ellis M, Figueroa P, Kurz A, Roxby D, Sessler D, Sharon Y, Sobieraj-Teague M, Warkentin T, Webert K, Barty R, Liu Y, Eikelboom J. Analysis of red blood cell storage duration and in-hospital mortality using time dependent exposure: is the oldest blood bad? AABB Annual Meeting, 2017, San Diego, CA. Transfusion. 2017, 57 (suppl S3), 33A. Abstract No. C26-A02C.
  2. Solh Z, Rajagopal R, Thachil J, Chan A, Heddle N, Monagle P. International survey of the management of disseminated intravascular coagulation among pediatric and neonatal health care practitioners. XXVI Congress of the International Society on Thrombosis and Haemostasis (ISTH), 2017, Berlin, Germany. (Abstract PB 2164; Res Pract Thromb Haemost. 2017; 1[Suppl. 1]:1198-9)
  3. Solh Z, Rajagopal R, Thachil J, Chan AK, Heddle NM, Monagle P. Availability of Age-specific Coagulation Laboratory Values in Pediatric Hospitals vs. Combined Pediatric/Adult Hospitals: An International Perspective. International Society on Thrombosis and Hematology Congress, July 2017, Berlin, Germany. Res Pract Thromb Haemost. 2017; 1(Suppl S1):PB 1144:530.
  4. Santagostino E, Kenet G, Oldenburg J, Chan A, Boggio L, Altisent C, Seifert W, the PROLONG-9FP Investigators. High adherence in adult and pediatric patients with hemophilia B receiving prophylaxis with rIX-FP. XXVI Congress of the International Society on Thrombosis and Haemostasis (ISTH), 2017, Berlin, Germany. (Abstract PB 1816; Res Pract Thromb Haemost. 2017; 1[Suppl. 1]:807)
  5. Schuster SJ, bishop MR, Tam C, Waller EK, Borchmann P, McGuirk, Jager U, Jaglowski S, Andreadis C, Westin J, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Anak O, Pacaud L, Awasthi R, Tai F, Salles G, Maziarz RT. Global pivotal phase 2 trial of the CD19-targeted therapy CTL019 in adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL)- an interim analysis. 22nd Congress of the European Hematology Association, 2017, Madrid, Spain.
  6. Duncan J, Lima A, Cserti-Gazdewich CM, Cober N, Di Tomasso J, De Biasio L, Harrison L, McShane K, Syer K, Heddle N. Ontario's Transfusion Transmitted Injury Surveillance System: New Tools to Reduce Complexity in Adverse Transfusion Event Reporting. Canadian Society for Transfusion Medicine Annual Meeting, 2017, Ottawa, ON.
  7. MacIsaac J, Siddiqui R, Jamula E, Li N, Baker S, Webert K, Heddle N, Arnold DM. Rituximab as an alternative to intravenous immune globulin for autoimmune diseases. Canadian Society for Transfusion Medicine Annual Meeting, 2017, Ottawa, ON.
  8. Movilla RV,  Lucier KJ, Parvizian MK, Siddiqui R, Gabriele EH, Bourque M,  MacIsaac J, Moorehead PC, Chan AK, Heddle NM, Lane SJ. Parent preferences in obstetrical and perinatal care in hemophilia: a survey of hemophilia treatment centre providers. Canadian Society for Transfusion Medicine Annual Meeting, 2017, Ottawa, ON.
  9. Shih AW, Jo D, De Wit K, Bhagirath V, Castellucci LA, Yeh C, Thoma B, Elahie A, Heddle NM, Chan TM. Performing a Massive Online Needs Assessment for Developing a Learner-Centered Online Curriculum for the Management of Bleeding Through the Use of Social Media: A SoMe-KTE3 Project. Canadian Society for Transfusion Medicine Annual Meeting, 2017, Ottawa, ON.
  10. Shih AW-Y, Li N, Barty RL, Cook RJ, Crowther MA, Heddle NM. Utilizing electronic health records to audit red blood cell transfusion ordering practices in four Ontario tertiary care centers. Canadian Society of Transfusion Medicine Annual Meeting, 2017, Ottawa, ON. 
  11. Shih, A.W., Lane, S.J., Barty, R.L, Crowther, M.A., Heddle, N.M. (2017). Determining the factors for reassessment after transfusion: a Canadian survey. CSTM Annual Meeting, 2017, Ottawa, ON.
  12. Chasse M, Liu Y, Hsia C, Thompson T, Heddle NM, Eckert K, Kinney J, McIntyre L, Tinmouth A. Albumin utilization 2011-14. The data collection strategy: albumin proof of concept project. CSTM Annual Meeting, 2017, Ottawa, ON.
  13. Bussel JB, Arnold DM, Cooper N, Khalafallah AA, Boxer M, Liles D, Ghanima W, McCrae K, Zayed H, Cadieux B, Duliege AM. Long-Term Maintenance of Platelet Responses in Adult Patients with Persistent/Chronic Immune Thrombocytopenia Treated with Fostamatinib: 1-Year Efficacy and Safety Results. Blood. 2017;130(1):16.
  14. Mithoowani S, Shah N, Ejaz R, Barty R, Li N, Nazy I, Kelton JG, Arnold DM. Emergency Management of Patients with Immune Thrombocytopenia and Severe Bleeding. Blood. 2017; 130(1):4852.
  15. Balitsky AK, Kelton JG, Nazy I, Aubie B, Clare R, Jaffer AM, Arnold DM. Use of Anticoagulation in Patients with Immune Thrombocytopenia. Blood. 2017;130(1):2313.

2016

PLACEHOLDER TITLE
  1. Doncaster C, Webert K. BloodBrief: Increasing Awareness to Influence Transfusion Practice. AABB Annual Meeting. Transfusion. 2016; 56(S4):27A.
  2. Doncaster C, Webert K. Understanding Hospital Inventory. AABB Annual Meeting. Transfusion. 2016; 56 (S4):239A.
  3. Lim W, Crowther M, Wang L, Douketis J, Schnurr T, Moreau C, Clase C, Rodger M, Yeo E, Leblanc M, McFarlane P, Ribic C. Assessment of low molecular weight heparin accumulation in patients with chronic kidney disease: Results from the TRIVET study. J Thromb Haemost. 2016. Presented at the ISTH SSC, Montpellier, France (poster).
  4. Spradbrow J, Cohen R, Lin Y, Armali C, Collins A, Webert K et al. Determining the quality benchmark metric for appropriate use of red blood cell transfusion: A quality audit at 10 hospitals. CSTM Annual Meeting 2016.
  5. Diep C, Shih AW, Jamula E, Lin Y, Armali C, Heddle NM, Traore A, Doherty J, Shah N, Hillis CM. Audit of intravenous immune globulin (IVIG) indications and effectiveness in Ontario tertiary care centres. Poster presented at Western Student Research Conference, London, ON, Mar. 19, 2016.
  6. Jamula E, Barty RL, Liu Y, Arnold DM, Heddle NM. Building TRUST: The Transfusion Registry for Utilization Surveillance and Tracking. Accepted for presentation at the Society of Clinical Research Associates Annual Conference 2016.
  7. Heddle NM, Cook RJ, Barty RL, Liu Y, Arnold DM, Crowther MA, Devereaux PJ, Ellis M, Figueroa P, Hirsh J, Kurz A, Roxby D, Sessler DI, Sobieraj-Teague M, Warkentin TE, Webert KE, Eikelbooom JW. Informing fresh versus old red cell management (INFORM) trial: A large international pragmatic randomized trial. AABB Annual Meeting, Orlando, FL, Oct. 22-25, 2016. Transfusion. 2016; 56(Suppl S4):5A:P6-030A.
  8. Zeller M, Aandahl A, Apelseth T, Callum J, Dunbar NM, Garritsen H, Hancock H, Kutner J, Manukian B, Mizuta S, Okuda M, Pagano MB, Poglod R, Rushford K, Selleng K, Sorensen C, Sprogoe U, Staves J, van Wordragen M, Weiland T, Wendel S, Ziman A, Heddle NM, Yazer MH, on behalf of the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Group O utilization patterns: The GROUP study. AABB Annual Meeting, Orlando, FL, Oct. 22-25, 2016. Transfusion. 2016; 56(Suppl S4):14A:S25-020B.
  9. Zeller M, Barty RL, Iserman EC, Liu Y, Wang G, Vasilic L, Gerrie W, Crowther M, Arnold DM, Heddle NM, Iorio A. Developing a data-driven research program: An integrated database network tool driving education and research forward. AABB Annual Meeting, Orlando, FL, Oct. 22-25, 2016. Transfusion. 2016; 56(Suppl S4):237A:AP52.
  10. Solh Z, Chan A, Heddle NM. Transfusion premedication practices in pediatrics: Results of a Canadian survey. AABB Annual Meeting, Orlando, FL, Oct. 22-25, 2016. Transfusion. 2016; 56(Suppl S4):19A:S39-030B.
  11. Zeller M, Barty RL, Wang G, Bourque M, Ramsay NS, Liu Y, Iorio A, Heddle NM. Antibodies of undetermined significance in solid-phase technology, exploring incidence, associated patient factors and laboratory impact. AABB Annual Meeting, Orlando, FL, Oct. 22-25, 2016. Transfusion. 2016; 56(Suppl S4):132A:SP253.
  12. Parvizian SM, Heddle NM, Athale U, Goldman MR, Verhovsek M. Red cell antigen genotyping compared to serological phenotyping in sickle cell disease patients in Canada: Potential for reducing alloimmunization. AABB Annual Meeting, Orlando, FL, Oct. 22-25, 2016. Transfusion. 2016; 56(Suppl S4):153A:SP314.
  13. Zeller M, Barty RL, Elahie A, Dunbar NM, Flanagan P, Garritsen H, Kutner J, Pagano MB, Poglod R, Rogers TS, Staves J, van Wordragen M, Zwaginga J, Heddle NM, Yazer MH, O Collaborative. How many AB plasma units were infused? The HABSWIN study. AABB Annual Meeting, Orlando, FL, Oct. 22-25, 2016. Transfusion. 2016; 56(Suppl S4):169A:SP361.
  14. Shih AW, Jamula E, Diep C, Lin Y, Armali C, Heddle NM, Traore A, Doherty J, Shah N, Hillis CM. Audit of provincial IVIG request forms and efficacy documentation in four tertiary care centres in Canada. AABB Annual Meeting, Orlando, FL, Oct. 22-25, 2016. Transfusion .2016; 56(Suppl S4):177A:SP384.
  15. Zeller MP, Barty R, Liu Y, Wang G, Ramsay N, Arnold DM, Heddle NM. Understanding Intravenous iron ordering practices for inpatients and outpatients at a large academic institution. Transfusion Medicine Reviews, 30(3), 147. November 2016.
  16. Kenet G, Chambost H, Male C, Lambert T, Alvarez-Roman MT, Halimeh S, Chan A, Barnes C, Chernova T, Blatny J, Mancuso ME, Meunier S, Komrska V, Laws HJ, Morfini M, Curtin J, Blazek B, Voigt C, Jacobs I, Santagostino E. Recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated children with hemophilia B: efficacy and safety from a Phase 3 pivotal clinical trial. 9th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD), 2016, Malmo, Sweden. (Abstract P004; Haemophilia 2016, 22 [Suppl 2]:22-23)
  17. Kenet G, Chambost H, Male C, Lambert T, Alvarez-Roman MT, Halimeh S, Chan A, Barnes C, Chernova T, Blatny J, Mancuso ME, Meunier S, Komrska V, Laws HJ, Morfini M, Curtin J, Blazek B, Voigt C, Jacobs I, Santagostino E. Efficacy, pharmacokinetics (PK) and safety results of a phase 3 clinical study of recombinant fusion protein linking coagulation factor IX with albumin (rIX-FP) in previously treated children with hemophilia B. 60th Annual Meeting of the Society of Thrombosis and Haemostasis Research (GTH), 2016, Muenster, Germany. (Abstract PO8-7)
  18. Xu ZL, Gantioqui J, Stevic I, Chan AKC, Chan HHW. Effects of fondaparinux and rivaroxaban on clot formation in factor VIII-deficient, but von Willebrand factorsupplemented, plasma mimicking plasma samples obtained from hemophilia A patientsThrombosis and Hemostasis Summit of North America (THSNA), 2016, Chicago, IL.
  19. Strike K, Almonte T, Decker k, Goldsmith R, Nagel K, Waterhouse L, Chan AK. Adherence and the relationship to frequency of infusions in pediatric patients with hemophilia A and B. World Federation of Hemophilia (WFH) 2016 World Congress, 2016, Orlando, FL. (Haemophilia 22[Suppl 4]:7)
  20. Cui V, Nagel K, Decker K, Walton M, Chan A. Central venous access device (CVAD) insertion procedure for pediatric patients with severe hemophilia A: trends in Factor VIII (FVIII) replacement therapy. World Federation of Hemophilia (WFH) 2016 World Congress, 2016, Orlando, FL. (Haemophilia 22[Suppl 4]:97)
  21. Strike K, Squire S, Lawson W, Uy M, Chan A. Point of care ultrasonography in hemophilia: impact of prior experience and success on competency assessment/evaluation. World Federation of Hemophilia (WFH) 2016 World Congress, 2016, Orlando, FL. (Haemophilia 22[Suppl 4]:107)
  22. Kenet G, Chambost H, Male C, Lambert T, Alvarez-Roman MT, Halimeh S, Chan A, Barnes C, Chernova T, Blatny J, Mancuso ME, Meunier S, Komrska V, Laws HJ, Morfini M, Curtin J, Blazek B, Voigt C, Jacobs I, Santagostino E. The efficacy and safety of recombinant fusion protein linking coagulation factor IX with albumin (Rix-Fp) in previously treated children with hemophilia B: Results of a phase 3 pivotal clinical trial. European Congress on Thrombosis and Haemostasis (ECTH), 2016, the Hague, the Netherlands. (Abstract ECTH-217)
  23. Ishac Nazy, Jane C. Moore, Rumi Clare, James W. Smith, Nikola Ivetic, Vanessa D'Souza, John G. Kelton and Donald M. Arnold. Autoantibodies to Thrombopoietin and the Thrombopoietin Receptor in Patients with Immune Thrombocytopenia. ASH, 2016, San Diego, CA.
  24. Bezverbnaya K, Helsen C, Denisova G, Aarts C, Evelegh C, Mian H, Foley R, Bramson J. Adoptive immunotherapy. (includes pre-clinical in vitro and animal models of adoptive immunotherapy including T cells, regulatory cells, dendritic cells and other cell populations designed to treat malignancies or infections and vaccine therapies. American Society of Hematology, 2016, San Diego, CA.
  25. Tseng E, Crowther MA, Hillis CM. Bridging anticoagulation for interruption of warfarin in a patient with atrial fibrillation. CMAJ. 2016 Mar 15;188(5):361-2.
  26. Elahie A, Verhovsek M, Fazari S, Warkentin TE. Implementation of blood group genotyping as routine testing for sickle cell patients in a multi-site Transfusion Medicine laboratory program. Canadian Society of Transfusion Medicine (CSTM) Annual Meeting, 2016, Vancouver, BC. 

2015

PLACEHOLDER TITLE
  1. Doncaster C, Webert KE. Contingency planning requires hospital participation. Canadian Society of Transfusion Medicine (Abstract #082), Annual Meeting, Winnipeg MB, 2015.
  2. Thompson T, Tinmouth AT, Pinkerton P, Callum J, Hsia CC, Shperd L, Webert KE. A repeat provincial audit of frozen plasma (FP) and prothrombin complex concentrates (PCCs). AABB Annual Meeting. Transfusion. 2015; 55 (supplement 3), 162A.
  3. Linkins LA, Warkentin TE, Pai M, Shivakumar S, Manji R, Wells PS, Wu CM, Nazi I, Crowther MA. Rivaroxaban for treatment of suspected or confirmed heparin-induced thrombocytopenia study. Blood (ASH Annual Meeting Abstracts) 2015; 126 (23): 3468. 2015 Dec 4 Epub ahead of print. [Poster presentation, Poster Session III: "Disorders of Platelet Function or Number," Hall A, Orange
  4. County Convention Center, Level 2, 57th American Society of Hematology Annual Meeting, Orlando, CA, 1800-2000h, 7 Dec 15.]
  5. Al-Habsi KS, Shih AW, Barty RL, Wang G, Elahie A, Azzam M, Siddiqui R, Parvizian M, Heddle NM, Athale U, Goldman M, Verhovsek M. Red cell antigen genotyping compared to standard serological phenotyping in sickle cell disease patients in Canada: Potential for reducing alloimmunization. ASH Annual Meeting and Exposition, Orlando, FL, Dec. 5-7, 2015. Blood 2015; 126(23):3404.
  6. Sholapur NS, Hillis CM, Crowther MA, Leber B, Khokhar F, Cook RJ, Barr R, Heddle NM. Assessing disease stability of patients with myelodysplastic syndrome for an age of blood randomized controlled trial: A chart review. ASH Annual Meeting and Exposition, Orlando, FL, Dec. 5-7, 2015. Blood 2015; 126(23)5252.
  7. Sholapur NS, Lane S, Hillis C, Crowther MA, Leber B, Cook RJ, Barr R, Heddle NM. A qualitative research study to understand post-transfusion well-being in patients with myelodysplastic syndromes. ASH Annual Meeting and Exposition, Orlando, FL, Dec. 5-7, 2015. Blood 2015; 126(23):4446.
  8. Iorio A, Krishnan S, Myrén K, Lethagen S, Mccormick N, Karner P. Comparisons of factor consumption for routine prophylaxis and bleeding during episodic therapy with recombinant factor Viii Fc fusion protein and conventional recombinant factor Viii. Value Health. 2015 Nov;18(7):A660.
  9. Barty RL, Cook RJ, Liu Y, Acker J, Eikelboom JW, Heddle NM. Exploratory analysis of the association between donor sex and in-hospital mortality in transfusion recipients. AABB Annual Meeting, Anaheim, CA, Oct. 24-27, 2015. Transfusion 2015: 55(Suppl 3):23A:S41-030F.
  10. Heddle NM, Liu Y, Acker JP, Barty RL, Eikelboom JW, Arnold DM, Hsia C, O’Brien SF, Webert KE, Cook RJ. Exploratory analysis of a blood processing method and in-hospital mortality. AABB Annual Meeting, Anaheim, CA, Oct. 24-27, 2015. Transfusion 2015; 55(Suppl 3):23A:S40-030F.
  11. Delaney M, Taune-Wikman A, van de Watering LM, Verdoes J, Emery SP, Murphy MF, Flach S, Staves J, Arnold DM, Kaufman RM, Ziman A, Harm SK, Fung M, Dunbar NM, Buser A, Meyer E, Savoia H, Abeysinghe P, Heddle NM, Tinmouth A, Traore AN, Yazer MH, on behalf of the BEST Collaborative. Red blood cell transfusion antigen matching influence on gestational outcomes (AMIGO) study. AABB Annual Meeting, Anaheim, CA, Oct. 24-27, 2015. Transfusion 2015; 55(Suppl 3):25A:S43-030F.
  12. Shih A, Bhagirath V, Liaw P, Acker J, Eikelboom JW, Heddle NM. Quantification of cell free DNA in red blood cell concentrates produced via buffy coat (B1) OR whole blood (B2) methods. AABB Annual Meeting, Anaheim, CA, Oct. 24-27, 2015. Transfusion 2015; 55(Suppl 3):9A:S9-010B.
  13. Rebulla P, Vaglio S, Aprili G, Beccaria F, Coluzzi S, Girelli G, Graf M, Isernia P, Marconi M, Olivero B, Rinaldi M, Salvaneschi L, Scarpato N, Strada P, McCullough J, Heddle NM, Grazzini G. Clinical efficacy and safety of platelets in additive solution treated with two commercial pathogen reduction technologies. AABB Annual Meeting, Anaheim, CA, Oct. 24-27, 2015. Transfusion 2015; 55(Suppl 3):3A:P2-030A.
  14. Zeller M, van de Watering LM, Heddle NM, Yazer MH, on behalf of the BEST Collaborative. Group O and RhD-negative utilization patterns and associated hospital policies: A multicenter, international study. AABB Annual Meeting, Anaheim, CA, Oct. 24-27, 2015. Transfusion 2015; 55(Suppl 3):154A:SP249.
  15. Barty RL, Pai M, Liu Y, Cook RJ, Arnold DM, Heddle NM. Group O red blood cells: Where is universal donor blood being used? AABB Annual Meeting, Anaheim, CA, Oct. 24-27, 2015. Transfusion 2015; 55(Suppl 3):153A:SP248.
  16. Al-Habsi K, Shih AW-Y, Barty RL, Wang G, Elahie A, Azzam M, Siddiqui R, Parvizian M, Heddle NM, Athale U, Goldman M,Verhovsek M. Red cell antigen genotyping compared to standard serological phenotyping in sickle cell disease patients in Canada: Potential for reduction alloimmunization. Poster presented at Lifeline: The 2015 Pan-Canadian Thalassemia Conference, Toronto, ON, September 25-26, 2015.
  17. Shih A, Bhagirath V, Liaw P, Acker J, Eikelboom JW, Heddle NM. Quantification of cell free DNA in red blood cell concentrates produced via buffy coat (B1) OR whole blood (B2) methods. ISTH 2015 Congress, Toronto, ON, June 20-25, 2015. Journal of Thrombosis and Haemostasis Jun 2015; 13(Suppl. 2):468: Abst PO570-MON
  18. Schulman S, Carrier M, Lee AY, Shivakumar S, Blostein M, Spencer FA, Solymoss S, Barty RL, Wang G, Heddle NM, Douketis JD. Perioperative management of Dabigatran: A prospective cohort study. ISTH 2015 Congress, Toronto, ON, June 20-25, 2015. Journal of Thrombosis and Haemostasis Jun 2015; 13(Suppl. 2):203: Abst OR282.
  19. Manning M, Heddle NM, Arnold DM, Crowther MA, Siegal D. Interventions to reduce blood loss from laboratory testing in critically ill patients and impact on transfusion: A systematic review. ISTH 2015 Congress, Toronto, ON, June 20-25, 2015. Journal of Thrombosis and Haemostasis Jun 2015; 13(Suppl. 2):974: Abst PO616-WED.
  20. Pai MDelaney J, Salib M, Panju M, Schulman S. Direct-Acting Oral Anticoagulants In The Real World: Insights Into Health Care Providers’ Understanding Of Medication Dosing And Use. J Throb Haem 2015: 13(S2).
  21. Traore AN, Chan AKC, Iorio A, Heddle NM, Walker I and Association of Hemophilia Clinic Directors of Canada. Utilization of anti-inhibitors products and inhibitors status of severe hemophilia patients: 5 years national data from the Canadian hemophilia assessment and resource management system. ISTH 2015 Congress, Toronto, ON, June 20-25, 2015. Journal of Thrombosis and Haemostasis Jun 2015; 13(Suppl. 2):362: Abst PO276-MON.
  22. Iorio A, Krishnan S, Myren K-J, Lethagen S, McCormick N and Karner P. Indirect comparisons of factor consumption, bleeding rates, and infusion frequencies during routine prophylaxis with recombinant factor IX FC fusion protein and other recombinant factor IX products. Journal of Thrombosis and Haemostasis 2015, 13 (Suppl. 2); 1–997. PO171-Mon
  23. Iorio A, Blanchette V, Blatny J, Collins P, Croteau S, Dunn A, Fischer K, Hermans C, Kavakli K, Jackson S, James P, Mammen S, Morfini M, Navarro-Ruan T, Neufeld EJ, Ozelo M, Radossi P, Rangarajan S, Ruiz- Saez A, Teitel J, Thabane L, Young G and Xi M. A population approach to hemophilia pharmacokinetics. Wapps: a web-service for bayesian post hoc estimation. Journal of Thrombosis and Haemostasis 2015, 13 (Suppl. 2); 1–997. AS122.
  24. Chai-Adisaksopha C, Iorio A, Crowther MA, de Miguel J, Salgado E, Zdraveska M, Monreal M. Switching to Warfarin after 6-Month Completion of Anticoagulant Treatment for Cancer-Associated Clinically Relevant Thrombosis. Blood 2015:126 (23).
  25. Chai-Adisaksopha C, Cheah M, AlKindi SY, Iorio A, Crowther MA, and Linkins LA. Bleeding in patients receiving Low-Molecular-Weight Heparin for cancer-associated thrombosis. Blood 2015:126 (23).
  26. Chai-Adisaksopha C, Hillis C, Lim W, Boonyawat K, Crowther M. Hemodialysis for the treatment of dabigatran-associated bleeding: A systematic review of the literature. Presented at the International Society on Thrombosis and Hemostasis meeting, Toronto, ON, June 2015 (poster)
  27. Matino D, Gargaro M, Santoro C, Castaman G, Fallarino F, Iorio A. Investigating potential determinants of ITI success using immune gene expression profiling: a preliminary study. Journal of Thrombosis and Haemostasis. 2015, 13(Suppl 2); 1-997.
  28. Iorio A, Rentz A, Balantac Z, Hoxer CS. Assessing the indication and success of treatment for haemopilia patients: results from a Delphi panel. Journal of Thrombosis and Haemostasis 2015, 13 (Suppl 2); 1-997.
  29. Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Modeling the impact of potential differences in real-world adherence with extended-half-life conventional factor Vii and Ix on bleeding. P. Value Health. 2015 Nov; 18(7):A660-1.
  30. Iorio A, Krishnan S, Myrén K, Lethagen S, McCormick N, Karner P. Factor consumption for prophylaxis and treatment of bleeding: recombinant factor Ix Fc fusion compared with conventional recombinant Factor Ix. Value Health. 2015 Nov; 18(7):A660. 
  31. Matino D, Gargaro M, Santoro C, Castaman G, Fallarino F, Iorio A. Investigating potential determinants of ITI success using immune gene expression profiling: a preliminary study. Journal of Thrombosis and Haemostasis. 2015, 13(Suppl 2); 1-997.

2014

PLACEHOLDER TITLE
  1. Arnold DM, Clare R, Salib M, Clayden R, Wang G, Nazi I and Kelton JG. The McMaster ITP Registry: Assessing the Prevalence, Clinical and Laboratory Features of Immune Thrombocytopenia. Blood 124(21) December 6, 2014.
  2. Foley SR, Rock G, Barth D, Arnold DM, Webert K, Yenson P, Kelton JG, Clark WF and Li L. A Phase II study evaluating the efficacy of Rituximab in the management of patients with relapsed or refractory TTP. Blood 124(21) December 6, 2014.
  3. Salib M, Clayden R, Clare R, Wang G, Warkentin TE, Crowther MA, Lim W and Arnold DM. Difficulties in establishing the cause of thrombocytopenia among ambulatory patients referred to hematology: An agreement study. Blood 124(21) December 6, 2014.
  4. Nazi I, Arnold DM, Smith J, Warkentin TE, Moore J, Horsewood P and Kelton JG. Low level platelet-activating antibodies in the patients suspected of having heparin-induced thrombocytopenia but testing negative in the “gold standard” functional test. Blood124(21) December 6, 2014.
  5. Zeller M, Cserti-Gazdewich CM, Delage G, Heddle NM. Donath-Landsteiner testing: A retrospective review of testing during seven years at a large academic health center and results of a national survey. AABB Annual Meeting, Philadelphia, PA, Oct. 25-28, 2014. Transfusion 2014; 54(Suppl):225A: Abst A3-030B.
  6. Lieberman L, Wang G, Jaffer A, Heddle NM. A retrospective review of platelet refractoriness in a cohort of pediatric oncology patients. AABB Annual Meeting, Philadelphia, PA, Oct. 25-28, 2014. Transfusion 2014; 54(Suppl):135A: Abst SP198.
  7. Rahman S, Heddle NM, Hillis C. Impact of treatment of Myelodysplastic Syndromes (MDS) on red blood cell (RBC) transfusion requirements: A systematic review of randomized controlled trials. Canadian Conference on Myelodysplastic Syndromes (CCMDS), Banff, Alberta, Sept. 12, 2014.
  8. Traore A, Chan A, Warner M, Iorio A, Wu J, Stoffman J, Tinmouth A, Teitel J, Heddle NM, Walker I. Factor VII deficiency patients: 5 years factors concentrates utilization trend based on the Canadian Hemophilia Assessment and Resource Management System (CHARMS). World Federation of Hemophilia (WFH) 2014 World Congress, Melbourne, Australia, May 11-15, 2014. Haemophilia 2014; 20(Suppl. 3):105.
  9. Khair K, Cruz MS, Werner S, Knaub S, Iorio A and on behalf of Wil-20 working group. Surveillance study of safety and efficacy of aVWF/ FVIII concentrate in patients with von willebrand disease (WIL-20) – a planned interim analysis. Journal of Thrombosis and Haemostasis 2015, 13 (Suppl. 2); 1–997. PO662-Mon.
  10. Chai-Adisaksopha C, Hillis CM, Thabane L, Iorio A. Systematic review of definitions and reporting of bleeding outcome measures in hemophilia. Blood 2014 (ASH Annual Abstracts) 124 (21) 2821.
  11. Jackson S, Yang M, Minuk L, St-Louis J, Sholzberg M, Card R, Iorio A, Poon MC. An evaluation of whether the ankle is now the dominant site of chronic hemophilic arthropathy in young adults with severe hemophilia. Haemophilia. 2014 May 1; 20:73.
  12. Iorio A, Krishnan S, Huynh L, Karner P, Duh MS, Yermakov S. An indirect comparison of the efficacy of prophylactic use of rFIXFc and other rFIX products and simulation of the effect of compliance on effectiveness. Haemophilia. 2014 May 1; 20:117-8.
  13. Strike K, Smith F, Chan A, Almonte T, Chaston C, Decker K, Goldsmith R, Matsui N, Nagel K, Orschel C, Walker I, Waterhouse L,Iorio A. Assessment of patient preferences and perceived value of the comprehensive interdisciplinary combined hemophilia and orthopedic clinic using a validated questionnaire. Haemophilia. 2014 May 1; 20:146.
  14. Iorio A, Barbara AM, Mathew P, Rivolta GF, Romanov VV, Roussel-Robert V, Tagliaferri A, Windyga J. Investigating determinants of inhibitor development to factor VIII molecules in previously treated hemophilia A patients. Haemophilia. 2014 Feb 1; 20:38.
  15. Marcucci M, Cheng J, Romanov V, Thabane L, Iorio A. The use of FVIII concentrate in hemophilia A patients with low titer inhibitors or a personal history of inhibitor: a meta-analysis of advate post-authorization safety studies in different countries. Haemophilia. 2014 Feb 1; 20:42.
  16. Iorio A. Does product type influence the development on inhibitor in PTPs and PUPs? Haemophilia. 2014 Feb 1; 20:6.
  17. Sun J, Yang R, Zhao Y, Wang X, Wu J, Zhang X, Teng B, Guan T, Li K, Iorio A. Factors influencing quality of life in Chinese adults with hemophilia: Results from the HERO study. Haemophilia. 2014 May 1; 20:170.
  18. Chai-Adisaksopha C, Hillis CM, Thabane L, Iorio A. A Systematic review of definitions and reporting of bleeding outcome measures in hemophilia. Blood 2014 (ASH Annual Abstracts) 124 (21) 2821.
  19. Xi M, Navarro-Ruan T, Mammen S, Blanchette VS, Hermans CR, Morfini M, Collins PW, Fischer K, Neufeld EJ, Young G, Kavakli K, Radossi P, Dunn A, Thabane L, Iorio A. Systematic review of the published evidence on the pharmacokinetic characteristics of factor VIII and IX concentrates. Blood 2014 (ASH Annual Abstracts) 124 (21).

2013

PLACEHOLDER TITLE
  1. Solh Z, Athale UH, Barty RL, Jamula E, Liu Y, Wang G, Hamilton K, Heddle NM. Transfusion related alloimmunization in children: Epidemiology and effects of chemotherapy (TRACE-EC Study). ASH Annual Meeting 2013:1161.
  2. Schulman S, Douketis J, Barty RL, Lee AYY, Carrier M, Spencer F, Blostein MD, Solymoss S, Shivakumar S, Wang G, Heddle NM. Perioperative management of patients on Dabigatran - a prospective cohort study. ASH Annual Meeting 2013:3637.
  3. Cook RJ, Heddle NM, Lee K-A, Liu Y, Barty RL, Eikelboom J. Exposure to ABO compatible but non-group identical blood and in-hospital mortality. ASH Annual Meeting 2013:3651.
  4. Jaffer A, Barty RL, Jamula E, Wang G, Liu Y, Leber B, Heddle NM, Athale UH. Transfusion-related iron overload: A covert risk of supportive cancer care. ASH Annual Meeting 2013:3656.
  5. Ning S, Barty RL, Liu Y, Heddle NM, Arnold DM. The use of platelet transfusions in the intensive care unit and impact on platelet count: A 30,000 patient registry study. ASH Annual Meeting 2013:1154.
  6. Warkentin TE, Basciano PA, Bernstein RA. Spontaneous heparin-induced thrombocytopenia syndrome: two new cases and a proposal for defining this disorder. Blood 2013 Oct 21; 122 (21): 2328 [Abstr]. Poster presentation, Session “Disorders of Platelet Number of Function,” 1830-2030h, Ernest N. Morial Convention Center, Hall E, New Orleans, LA, 8 Dec 13.
  7. Linkins LA, Bates SM, Lee AYY, Warkentin TE. Combination of 4T’s score and rapid gel centrifugation assay excludes HIT in a prospective cohort study. Blood 2013 Oct 21; 122 (21): 3535 [Abstr]. Poster presentation, Session “Platelet Disorders,” 1830-2030h, Ernest N. Morial Convention Center, Hall E, New Orleans, LA, 9 Dec 13.
  8. Williamson D, Albert M, Heels-Ansdell D, Arnold DM, Lauzier F, Lim W, Crowther M, Zarychanski R, Cook D. Thrombocytopenia in the critically ill: Incidence, risk factors and impact on transfusions, bleeding, mortality. Critical Care Med Jan 2013; 40(12) (Suppl. 1):1-328.
  9. Warkentin TE, Sheppard JI. Serological investigation of 20 patients re-exposed to heparin with a previous history of heparin-induced thrombocytopenia. J Thromb Haemost 2013; 11 (Suppl. 2): 132. [Oral Communication OC-21.3. XXIVth Congress of the International Society on Thrombosis and Haemostasis, Mondriaan II, Amsterdam Rai, Amsterdam, Netherlands, 1 Jul 13.]
  10. Rehan M, Caruso N, Beattie J, Pai M, Don-Wauchope A. Optimizing The Use Of A Conversion Factor For Calculation Of Total Iron Binding Capacity From Transferrin. Clin Chem 2013; 59(S10):A145.
  11.  Krauel K, Valentin P, Fürll, Hammer E, Brandt S, Jensch I, Kreimann M, Warkentin TE, Greinacher A. Fibronectin inhibits anti-PF4/heparin antibody induced platelet activation and low fibronectin levels are a potential risk factor for developing clinical HIT. PB 2.40-2. Session: Heparin-induced thrombocytopenia (HIT): basic. XXIVth Congress of the International Society on Thrombosis and Haemostasis, Eposter. Moderator: Anne Bertling (Germany). Amsterdam Rai, Amsterdam, Netherlands, 2 Jul 13.
  12. Bakchoul T, Zöllner H, Amiral J, Delcea M, Panzer S, Warkentin T, Sachs U, Greinacher A. The clinical impact of anti-protamine/heparin antibodies in patients undergoing cardiac surgery. PB 3.08-5. Session: Heparin-induced thrombocytopenia (HIT): clinical-II. XXIVth Congress of the International Society on Thrombosis and Haemostasis, Eposter. Moderator: Tamam Bakchoul (Germany). Amsterdam Rai, Amsterdam, Netherlands, 3 Jul 13.
  13. E. Santagostino, S. Lentz, A. Iorio, A. K. Busk, L. Adab-Franch, J. Meunier, A. Regnault. Effect of turoctocog alfa on quality of life of children, adolescents and adults with haemophilia A: results from two clinical trials. Haemophilia (2013), 19 (Suppl. 2), 10-82.
  14. Iorio A, Cassis F, Querol F, Pilgaard T. Demographic characteristics of European respondents in the HERO study. Haemophilia (2013), 19 (Suppl. 2), 10—82.
  15. Iorio A, Cassis F, Querol F, Kalnins W, Pilgaard, T. Effects of Haemophilia on relationships, intimacy and family: European results from the HERO Study. Haemophilia (2013), 19 (Suppl. 2), 10—82.
  16. Iorio A, Querol F, Kalnins W, Pilgaard T. Access to Haemophilia Treatment Centres, treatment and information sources: European results from the HERO Study. Haemophilia (2013), 19 (Suppl. 2), 10-82PO044.
  17. Iorio A, Querol F, Pilgaard T. Quality of Life in adults with haemophilia: European results From the HERO Study. Haemophilia (2013), 19 (Suppl. 2), 10-82PO043.
  18. Iorio A and Buzzi A. Association of treatment regimen and location with bleed frequency, quality of life and co morbidities in adults and children with haemophilia from the HERO study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933. PO 128.
  19. Iorio A, Buzzi A, Benchikh El Fegoun S and Cooper D. Association between treatment regimen and quality of life assessed by EQ-5D-3L and pain interference in adults with haemophilia with and without inhibitors in the HERO study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933.
  20. Marcucci M, Cheng J, Oldenburg J, Schoenig-Diesing C, Matovinovic E, Romanov V, Thabane L and Iorio A. Meta-analysis of post authorization safety studies: worldwide postmarking surveillance of hemophilia A patients treated with antihemophilic factor recombinant plasma/albumin-free method rAHF-PFM. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538-7933.
  21. Sun J, Yang R, Zhao Y, Wang X, Wu J, Zhang X, Guan T and Iorio A. Quality of life and well-being of haemophilia patients and parents in China: subgroup analysis of the HERO study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538-7933.
  22. Athale A, Giguere A, Barbara A, Iserman E, and Iorio A. Developing a two-sided intervention to facilitate shared decision making in haemophilia: Decision Boxes for clinicians and brief patient decision aids for patients. Blood 2013 (ASH Annual Meeting Abstracts), 122 (21).
  23. Nugent D, Stain AM, Gregory M, Pericleous L, Cooper DL, Iorio A. Associations between inhibitors, treatment regimen, bleed frequency and healthcare practitioner utilization in the haemophilia treatment centre: global results from the HERO study. Value in Health 16 (2013) A1-A298.
  24. F Cassis, M Gregory, W Kalnins, T Wisniewski, DL Cooper, Iorio A. Associations between negative impact on employment or relationships and haemophilia treatment centre and healthcare practitioner utilization: Global Results from the HERO Study. Value in Health 16 (2013) A1-A298.
  25. Matino D, Iorio A, Gargaro M, Santagostino E, Santoro C, Di Minno G, Morfini M, Puccetti P and Fallarino F. Defective indoleamine 2, 3-dioxygenase induction is associated with inhibitor development in severe hemophilia A patients carrying F8 gene null mutations. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933.
  26. Federici AB, Castaman G, Iorio A, Bonduel M, D’Amico EA, Oliovecchio E, Santoro C, Siboni SM, Zieger B and Mannucci PM. Clinical efficacy and safety of DDAVP with or without tranexamic acid in inherited VWD: final results of the prospective and international study on 229 patients. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933.
  27. Iorio A, Nugent D, Stain AM, Gregory M, Pericleous L and Cooper D. Do inhibitors, treatment regimen and bleed frequency impact haemophilia treatment centre and provider utilization: an analysis of adults with haemophilia in the HERO study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933
  28. Marcucci M, Eichinger S, Iorio A, Douketis JD, Tosetto A, Baglin TPT, Cushman M, Palareti G, Poli D, Campbell TR and Kyrle PA. External validation and updating of the Vienna Prediction Model for recurrent venous thromboembolism using a pooled individual patient data database. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933.
  29. Iorio A, Nugent D, Stain AM, Gregory M, Pericleous L and Cooper D. Do inhibitors, treatment regimen and bleed frequency impact parent-directed haemophilia treatment centre and provider utilization: An analysis of parents of children with haemophilia in the HERO study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933.
  30. Iorio A, Cassis F, Gregory M, Kalnins W, Wisniewski T and Cooper D. Potential relationships between negative impacts on employment or relationships with haemophilia centre/provider utilization: An analysis of parents of children with haemophilia from the HERO study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933.
  31. Iorio A, Cassis F, Gregory M, Kalnins W, Wisniewski T and Cooper D. Potential relationships between negative impacts on employment or relationships and haemophilia treatment centre/provider utilization: an analysis of adults with haemophilia from the HERO study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538–7933.
  32. Iorio A, Forsyth A, Guelcher C, Buzzi A, Wisniewski T and Cooper D. Relationship of quality of life, pain and self-reported arthritis with activity, bleed rate and haemophilia treatment centre/provider utilization: results from the HERO study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538-7933. PO 125.
  33. Iorio A, Forsyth A, Querol F, Stain AM, Pericleous L and Cooper D. Does higher risk activity change bleed frequency and haemophilia treatment center/provider utilization in children with haemophilia: an analysis from the HERO Study. Journal of Thrombosis and Haemostasis 2013, 11 (Suppl 2) Jul ISSN 1538-7933.

2012

PLACEHOLDER TITLE
  1. Lambourne MD, Eltringham-Smith LJ, Gataiance S, Arnold DM, Crowther MA, Sheffield WP. Prothrombin complex concentrates reduce blood loss in mice rendered coagulopathic by warfarin but now dabigatran etexilate. Transfusion 2012; 3S:56A.
  2.  Arnold E, Walker I, Chan A, Webert KE, Lane S, Poon M-C, Rubin S, Heddle NM. What do Canadian men living with Hemophilia need to know to facilitate optimal disease management? A mixed methods approach. Haemophilia 2012; 18(Suppl 3):175.
  3.  Lane S, Walker I, Chan A, Heddle NM, Arnold E, Poon M-C, Minuk L, Jardine L, Chin-Yee I, Webert KE. Understanding health and treatment decision making among youth with hemophilia:  A qualitative approach. Haemophilia 2012; 18(Suppl 3):207.
  4.  Goodyear D, Wu J, Webert KE, Chan A, Poon M. The Canadian experience:  Severe factor V deficiency. Haemophilia 2012; 18(Suppl 3):184.
  5.  Strike KL, Chan AK, Ross K, Bos C, Almonte T, Decker K, Goldsmith R, Iorio A, Walker I, Webert KE, Waterhouse L. Osteochondral lesions of the ankle joint in patients with hemophilia A: A retrospective case series. Haemophilia 2012; 18(Suppl 3):128.
  6.  Bos C, Chan A, Atkinson S,  Bansosz K, Nagel K, Strike K, Webber C, Webert KE, Iorio A, Walker I. Nutritional intake and bone mineral density in boys with severe hemophilia. Haemophilia 2012; 18(Suppl 3):23. 
  7.  Bos C, Chan A, Strike K, Webert KE, Iorio A, Walker I, Almonte T, Decker K, Goldsmith R, Waterhouse L, , Nagel K. Low bone mineral density and increased fat mass in boys with severe hemophilia. Haemophilia 2012; 18(Suppl 3):23.
  8.  Tinmouth AT, Fergusson DA, McIntyre L, Callum J, Webert KE, Chatelain E, Shojania K. High rates of inappropriate frozen plasma utilization based on expert medical rating: Results of a multicentre Canadian study. Transfusion 2012; 52(Suppl):113A.
  9.  Lester C, Boychuk D, Webert KE, Warkentin TE. Impact of reformulation of Ortho Clinical Diagnostic 0.8% reagent red cells on antibody detection. Canadian Society of Transfusion Medicine 2012; 69.
  10.  Lester C, Boychuk D, Webert K, Warkentin TE. Impact of reformulation of Ortho Clinical Diagnostic 0.8% reagent red cells on antibody detection. Submitted to Canadian Society of Transfusion Medicine (CSTM), Mar 2012. [meeting in Halifax, NS, 24-27 May 2012]—published on-line.
  11. Warkentin TE, Sarode R, Johnston MA, Crowther MA. The pathogenesis of warfarin-associated venous limb ischemia and gangrene complicating cancer: clinical and laboratory parallels with heparin-induced thrombocytopenia (HIT). Thromb Res 2012; 129 (Suppl. 1): S159-S160. Abstr OC-10. Presented at the 6th International Conference on Thrombosis and Hemostasis Issues in Cancer, Bergamo, Italy, on 21 Apr 2012.
  12.  Ostermann M, McIntyre L, Lauzier F, Alhashemi J, Qushmaq I, Langevin S, Dodek P, Albert M, Khwaja K, Kutsiogiannis J, Burry L, Granton J, Friedrich J, Ferguson N, Marshall J, Finfer S, Heels-Ansdell D, Zytaruk N, Cook D, Sheppard J, Warkentin T, Crowther M. The consequences of suspected HIT in the ICU. Accepted for poster presentation, 32nd International Symposium on Intensive Care and Emergency Medicine. Brussels, Belgium, 20 Mar 2012.
  13.  Granton J, Friedrich J, Fergusson N, Finfer S, Kutsogiannis J, Lesur O, Lamontagne F,  Jacka M, Guyatt G, Lellouche F, Qushmaq I, Alhashemi J, Alsultan M, Sharpe M, Davies A,  Sheppard J, Zytaruk N, Crowther M, Warkentin TE, Cook D for the PROTECT Investigators, CCCTG and ANZICS-CTG.  Heparin-induced thrombocytopenia in the ICU: ELISA versus SRA testing. Am J Resp Crit Care Med 2012; 185: A1669.
  14.  Ostermann M, McIntyre L, Lauzier F, Alhashemi J, Qushmaq I, Langevin S, Dodek P, Albert M, Khwaja K,  Kutsiogiannis J, Burry L, Granton J, Friedrich J, Ferguson N, Marshall J, Finfer S, Heels-Ansdell D, Zytaruk N, Cook D, Sheppard J, WarkentinTE,  Crowther M, for the PROTECT Investigators, CCCTG and ANZICS-CTG. The consequences of suspected HIT in the ICU. Critical Care 2012; 16 (Suppl 1): P423.
  15. Hamilton K, Wang G, Sholapur NS, Carruthers J, Hsia CC, Hamm C, Blais N, Girard-Desbiens C, Pearson MA, Heddle NM, Arnold DM. Use of Intravenous Immune Globulin in Patients with Immune Thrombocytopenia Before and After Romiplostim: Real-World Experience. ASH Annual Meeting 2012: 4641.

Book Contributions

2019

PLACEHOLDER TITLE
  1. Warkentin TE. Heparin-induced thrombocytopenia (Chap 26). In: Kitchens CS, Kessler CM, Konkle BA, Streiff MB, Garcia DA, eds. Consultative Hemostasis and Thrombosis, 4th edn. Philadelphia: Elsevier, 2019: 491-527.
  2. Warkentin TE, Mithoowani S, Arnold DM. Acquired Thrombocytopnia (Chap. 14). In: Concise Guide to Hematology, Second Edition. Lazarus HM, Schmaier AH, eds. Cham, Switzerland: Springer International Publishing AG, 2019: 135-148.

2018

PLACEHOLDER TITLE
  1. Ning S, Heddle NM. Clinical Outcomes and Red Blood Cell Storage (Chap. 16). In: Hematologic Challenges in the Critically Ill. Shander A, Corwin H, eds. Cham, Switzerland: Springer International Publishing AG, 2018: 305- 320.
  2. Warkentin TE, Anderson JAM. How I treat patients with a history of heparin-induced thrombocytopenia. In: Blood® How I Treat. A Compendium for the Practicing Hematologist, Third Edition. Löwenberg B, Berliner N, eds. Washington, DC: American Society of Hematology, 2018: 76-87. 
  3. Pai M. Laboratory Evaluation of Hemostatic and Thrombotic Disorders. In: Hematology, Seventh Edition. Hoffman R, Benz EJ Jr., Silberstein LE, Heslop HE, Weitz JI, Anastasi J, Salama ME, Abutalib SA, eds. Elsevier, 2018.
  4. Solh Z, Chan AKC, Bhatt MD. Update in Pediatric Hematology. In: Update in Pediatrics. Piteau S, eds. Springer International Publishing, 2018: 313-330.
  5. Hillis C, Lim WP. Hematologic Manifestations of Systemic Disease: Liver Disease (Chap. 154). Hoffman, In: Hematology: Basic Principles and Practice, Seventh Edition. Hoffman, Benz, Silberstein, Heslop, Weitz, Anastasi, eds. Elsevier Canada, 2018.
  6. Warkentin TE. Heparin-induced thrombocytopenia (Chap. 133). In: Hematology: Basic Principles and Practice, Seventh Edition. Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, Salama ME, Abutalib AS, eds. Philadelphia: Elsevier, 2018: 1973-1983.
  7. Warkentin TE. Thrombocytopenia caused by platelet destruction, hypersplenism, or hemodilution (Chap. 132). In: Hematology: Basic Principles and Practice, Seventh Edition. Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J, Salama ME, Abutalib AS, eds. Philadelphia: Elsevier, 2018: 1955-1972.
  8. George JN, Arnold DM. UptoDate Chapter-Immune Thrombocytopenia (ITP) in Adults: Second Line and Subsequent Therapies. (www.uptodate.com), May 2018.

2017

PLACEHOLDER TITLE
  1. Verhovsek MM, Steinberg MH. Sickle Cell Disease as a Multifactorial Condition, (V3.0). In: Encyclopedia of Life Sciences (ELS). Chichester, England: John Wiley & Sons, Ltd, 2017. Accepted for publication.   
  2. Hillis C, Lim WP. Chapter 154: Hematologic Manifestations of Systemic Disease: Liver Disease. Hoffman, Hematology: Basic Principles and Practice, 7e. (in press)
  3. Shih AW, Heddle NM. A Primer on Biostatistics (Chap. 48). In: Practical Transfusion Medicine, Fifth Edition. Murphy MF, Roberts DJ, Yazer MH, eds. West Sussex, England: John Wiley & Sons, Ltd, 2017.
  4. Webert KE, Heddle NM. Investigation of acute transfusion reactions (Chap. 5). In: Practical Transfusion Medicine, Fifth Edition. Murphy MF, Pahphilon DH, Heddle NM, eds. West Sussex, UK: Wiley-Blackwell, 2017.
  5. Greinacher A, Warkentin TE. Heparin-induced thrombocytopenia (Chap. 31). In: Practical Transfusion Medicine, Fifth Edition. Murphy MF, Roberts DJ, Yazer MH, eds. Chichester, UK: John Wiley & Sons, Ltd, 2017: 341-356.  
  6. Greinacher A, Bakchoul T, Cuker A, Warkentin TE. Heparin-induced thrombocytopenia. In: Platelets in Thrombotic and Non-Thrombotic Disorders. Gresele P, Kleiman NS, Lopez JA, Page CP, eds. Gewerbestrasse, Switzerland: Springer International Publishing, 2017: 789-811.  
  7. Labarque V, Chan AKC, Williams S. Thromboembolic Events at Specific Organ Sites (Chap. 13). In: SickKids Handbook of Pediatric Thrombosis and Hemostasis, Second Edition. Blanchette VS, Breakey VR, Rebel-Vilk S, Brandao LR, eds. Switzerland: Karger, Basel, 2017: 200-216.

2016

PLACEHOLDER TITLE
  1. Hillis C and Lim WP. Chapter 154: Hematologic Manifestations of Systemic Disease: Liver Disease. Hoffman, Hematology: Basic Principles and Practice, 7e. (in press)
  2. Arnold DM, Ishac N, Smith JW, Warkentin TE. Management of immune- mediated thrombocytopenia. Rossi’s Principles of Transfusion Medicine, 5th edition, Chapter 21. Published April 2016.
  3. Siegal D, Barefah A, Verhovsek M, McFarlane A. Abnormalities in Red Blood Cells. In Principles and Practice of Hospital Medicine, 2nd ed; McKean S, Eds.; McGraw-Hill Professional: United States, 2016
  4. Siegal D, Lim W. Venous Thromboembolism in Hematology: Basic Principles and Practice, 7th edition Churchill Livingstone Elsevier, Philadelphia, 2016 pps.
  5. O’Hoski P, Foley R. Stem Cell Processing, Practical Transfusion Medicine, 5th Ed, Wiley-Blackwell, 2016.
  6. Callum JL, Lin Y, Pinkerton PH, Karkouti K, Pendergrast JM, Robitaille N, Tinmouth AT, Webert KE. Bloody easy 3, blood transfusions, blood alternatives and transfusion reactions, a guide to transfusion medicine. 4th. Toronto (ON): Sunnybrook and Women’s College Health Sciences Centre; 2016 in press.
  7. Webert KE, Hayward CPM. Chapter 176: Approach to Patients with Bleeding Disorders in: McKean S, Ross JJ, Dressler DD, Brotman DJ, Ginsberg JS (eds) Principles and practice of hospital medicine. American College of Physicians/McGraw Hill; New York 2016 in press.
  8. Webert KE, Heddle NM. Chapter 6: Investigation of acute transfusion reactions. In: Murphy MF, Pahmphilon DH, Heddle NM (Eds) Practical Transfusion Medicine, 5th Edition, Wiley-Blackwell, West Sussex UK, 2016 (in press).
  9. Verhovsek M, Chui DHK. Thalassemia. In Anemia: Pathophysiology, Diagnosis and Management, 1st ed; Benz E, Berliner N and Schiffman F, Eds; Cambridge University Press: UK (in press).
  10. Arnold DM, Zeller M, Smith J, Nazy I. Chapter 133 Diseases of Platelet Number: Immune Thrombocytopenia, Neonatal Alloimmune Thrombocytopenia, and Posttransfusion Purpua. Heamtology, 7th Edition Churchill Livingston (in press)

2015

PLACEHOLDER TITLE
  1. Arnold, DM and George J. UptoDate Chapter – Drug-induced Immune Thrombocytopenia. (www.uptodate.com) 2015.
  2. Sharathkumar AA, Goldenberg NA, Chan AKC. Chapter 7. Epidemiology, etiology,and pathophysiology of infection-associated venous thromboembolism in children. In: Pediatric Thrombotic Disorders. pp. 88-106. Goldenberg NA, Manco-Johnson MJ (Eds), Cambridge University Press, Cambridge, UK, 2015.

2014

PLACEHOLDER TITLE
  1. Warkentin TE. Diagnosis and management of heparin-induced thrombocytopenia. In: Bergan JJ, Bunke N, eds. The Vein Book, 2nd edn. New York, NY: Oxford University Press, 2013: in press.
  2. Webert KE, Smith JW, Arnold DM, Chan H, Heddle NM, Kelton JG. Chapter 20: Red cell, platelet, and white cell antigens. In: Greer JP, Arber DA, Glader B, List AF, Means Jr. RT, Paraskevas F, Rodgers GM (eds) Wintrobe’s Clinical Hematology, 13th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2014:509-546.
  3. Arnold DM, George JN. Approach to thrombocytopenia in adults. In: Benz EJ, Berliner N, Moake J, Brodsky R, LaCasce A (eds)Clinical Decision System on Hematology. Decision Support in Medicine LLC, Wilmington DE (in press).
  4. Pai MLaboratory Evaluation of Hemostatic and Thrombotic Disorders. In: Weitz J, editor Hoffman’s Hematology: Basic Principles and Practice, 7th edition. Elsevier. In press.
  5. Pai MDouketis J. VTE Prophylaxis for Nonorthopedic Surgery Patients. In: McKean S, Ginsberg J, editors. Principles and Practice of Hospital Medicine, 2nd edition. McGraw-Hill. In press.
  6. Iorio, A, Christine A. Lee, Erik E. Berntorp, W. Keith Hoots. The Epidemiology of Inhibitors in Hemophilia. In Textbook of Hemophilia, 3rd Edition .Wiley-Blackwell , May 2014.
  7. Arnold, DM and George J. UptoDate Chapter – Approach to Unexplained Thrombocytopenia.(www.uptodate.com) 2014.
  8. Arnold, DM and George J. UptoDate Chapter – Diagnosis of ITP. (www.uptodate.com) 2014.
  9. Arnold DM and George J. UptoDate Chapter – ITP: Second and Third Line Therapies.(www.uptodate.com) 2014
  10. Arnold DM and George J. UptoDate Chapter – Clinical Manifestations of ITP. (www.uptodate.com) 2014.
  11. Arnold DM and George J. UptoDate Chapter – Initial Treatment and Prognosis of ITP. (www.uptodate.com) 2014

2013

PLACEHOLDER TITLE
  1. Warkentin TE, Cuker A. Differential diagnosis of heparin-induced thrombocytopenia and scoring systems. In: Warkentin TE, Greinacher A (eds) Heparin-Induced Thrombocytopenia, 5th Edition. Boca Raton, FL: CRC Press, 2013:77-109.
  2. Warkentin TE, Greinacher A. Laboratory testing for heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds)Heparin-Induced Thrombocytopenia, 5th Edition. Boca Raton, FL: CRC Press, 2013:272-314.
  3. Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: An overview. In: Warkentin TE, Greinacher A (eds)Heparin-Induced Thrombocytopenia, 5th Edition. Boca Raton, FL: CRC Press, 2013:315-355.
  4. Warkentin TE, Eikelboom JW. Fondaparinux and other emerging anticoagulants to treat heparin-induced thrombocytopenia. In:Warkentin TE, Greinacher A (eds) Heparin-Induced Thrombocytopenia5th Edition. Boca Raton, FL: CRC Press, 2013:489-519.
  5. Warkentin TE. Heparin-coated intravascular devices and heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds)Heparin-Induced Thrombocytopenia5th Edition. Boca Raton, FL: CRC Press, 2013:573-590.
  6. Warkentin TE. Chapter 134: Thrombocytopenia caused by platelet destruction, hypersplenism, or hemodilution.  In: Hoffman R, Benz EJ Jr, Silberstein LE, Heslop HE, Weitz JI, Anastasi J (eds) Hematology: Basic Principles and Practice6th Edition, Philadelphia, PA: Churchill Livingstone Elsevier, 2013:1895-1912.
  7. Warkentin TE. Chapter 135: Heparin-induced thrombocytopenia. In:Hoffman R, Benz EJ Jr., Silberstein LE, Heslop HE, Weitz JI, Anastasi J (eds) Hematology: Basic Principles and Practice,6th Edition. Philadelphia, PA: Churchill Livingstone Elsevier, 2013:1913-1924.
  8. Greinacher A, Warkentin TE. Chapter 65: Acquired non-immune thrombocytopenia. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice,  6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2013:796-804.
  9. Warkentin TE, Marder VJ. Chapter 97: Overview of complex thrombohemorrhagic problems. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2013:1173-1177.
  10. Warkentin TE, Greinacher A. Chapter 108: Heparin-induced thrombocytopenia. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice, 6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2013:1292-1307.
  11. Warkentin TE. Chapter 109: Coumarin-induced skin necrosis and venous limb gangrene. In: Marder VJ, Aird WC, Bennett JS, Schulman S, White GC (eds) Hemostasis and Thrombosis: Basic Principles and Clinical Practice6th Edition. Philadelphia, PA: Lippincott Williams & Wilkins, 2013:1308-1317.
  12. Greinacher A, Warkentin TE. Chapter 30: Heparin-induced thrombocytopenia. In: Murphy MJ, Pamphilon DH, Heddle NM (eds)Practical Transfusion Medicine, 4th Edition. Hoboken, NJ: John Wiley and Sons, Ltd., 2013:322-334.
  13. Greinacher A, Warkentin TE, Chong BH. Chapter 42: Heparin-induced thrombocytopenia. In: Michelson AD (ed) Platelets3rdEdition. Waltham, MA: Elsevier, Inc., 2013:851-882.
  14. Warkentin TE. Chapter 25: Heparin-induced thrombocytopenia. In: Kitchens CS, Konkle BA, Kessler CM (eds) Consultative Hemostasis and Thrombosis3rd Edition. Philadelphia, PA: WB Saunders, Elsevier, 2013:442-473.
  15. Warkentin TE. Chapter 22.6.5: Acquired coagulation disorders. In: Warrell DA, Cox TM, Firth JD (eds) Oxford Textbook of Medicine,5th Edition. New York, NY: Oxford University Press, Inc., 2013 Jun 04—online update, available at http://oxfordmedicine.com/view/10.1093/med/ 9780199204854.001.1/med-9780199204854.
  16. Warkentin TE, Moore JC. Laboratory evaluation of heparin-induced thrombocytopenia. In: Kitchen S, Olson JD, Preston E (eds)Quality in Laboratory Hemostasis and Thrombosis, 2nd Edition. Hoboken, NJ: John Wiley & Sons, Ltd, 2013:174-191.
  17. Warkentin TE. History of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-Induced Thrombocytopenia5th Edition. Boca Raton, FL: CRC Press; 2013:1-23.
  18. Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A (eds) Heparin-Induced Thrombocytopenia5th Edition. Boca Raton, FL: CRC Press; 2013:24-76.
  19. Stanworth SJ, Brunskill SJ, Doree C, Hopewell S, Arnold DM. Chapter 46: Getting the most out of the evidence for transfusion medicine.  In: Murphy MF, Pamphilon DH, Heddle NM (eds) Practical Transfusion Medicine, 4th Edition.  Hoboken, NJ: John Wiley and Sons, Ltd., 2013:505-515.
  20. Arnold DM, Patriquin C, Toltl LJ, Nazi I, Smith J, Kelton JG. Chapter 133: Diseases of platelet number: Immune thrombocytopenia, neonatal alloimmune thrombocytopenia and post-transfusion purpura. In: Hoffman R, Benz Jr EJ. Silberstein L, Heslop H, Weitz JI (eds) Haematology: Basic Principles and Practices, 6th Edition. Philadelphia, PA: Elsevier-Saunders, 2013:1883-1894.
  21. O’Hoski P, Foley R. Stem Cell Processing, Practical Transfusion Medicine, 4th Ed, Wiley-Blackwell, 2016.

2012

PLACEHOLDER TITLE
  1. Heddle, NM, Webert KE. Chapter 2: Febrile Nonhemolytic transfusion reactions. In:  Popovsky MA, ed. Transfusion Reactions, 4thEdition. Bethesda, MD: AABB Press, 2012:53-97.
  2. Webert KE, Hayward CPM. Chapter 176: Approach to patients with bleeding disorders. In:  McKean SC, Ross JJ, Dressler DD, Brotman DJ, Ginsberg JS (eds) The Principles and Practice of Hospital Medicine. New York, NY: American College of Physicians/McGraw Hill, 2012:1463-1468.
  3. Pai MDouketis J. Chapter 60: Venous Thromboembolism (VTE) prophylaxis for hospitalized medical patients. In: McKean S, Ginsberg J (eds) Principles and Practice of Hospital Medicine. The McGraw-Hill Companies, Inc., 2012:407-410.
  4. Pai MDouketis J. Chapter 59: Venous thromboembolism (VTE) prophylaxis for patients requiring orthopedic surgery. In: McKean S, Ginsberg J (Eds) Principles and Practice of Hospital Medicine. The McGraw-Hill Companies, Inc., 2012:402-406.
  5. Pai MDouketis J. Chapter 58: Venous thromboembolism (VTE) prophylaxis for patients requiring non-orthopedic surgery. In: McKean S, Ginsberg J (Eds) Principles and Practice of Hospital Medicine. The McGraw-Hill Companies, Inc., 2012:397-401.
  6. Warkentin TE, Warkentin AE. Chapter 14: Acquired thrombocytopenia. In: Schmaier AH, Lazarus HM (Eds) Concise guide to hematology. Hoboken, NJ: Blackwell Publishing Ltd, 2012:154-173.
  7. Warkentin TE. Chapter 175: Quantitative abnormalities in platelets: thrombocytopenia and thrombocytosis. In: McKean SC, Ross JJ, Dressler DD, Brotman DJ, Ginsberg JS (eds) Principles and Practice of Hospital Medicine. New York, NY: McGraw-Hill Medical, 2012:1452-1462.
  8. Verhovsek M, McFarlane A. Abnormalities in Red Blood Cells. In Principles and Practice of Hospital Medicine, 1st ed; McKean S, Eds.; McGraw-Hill Professional: United States, 2012.
  9. Arnold DM, Patriquin C, Toltl LJ, Nazi I, Smith J, Kelton JG. Chapter 133: Diseases of Platelet Number: Immune Thrombocytopenia, Neonatal Alloimmune Thrombocytopenia and Post-transfusion Purpura. In: Haematology: Basic Principles and Practices, Sixth Edition, 2012. Edited by Ronald Hoffman, MD; Edward J. Benz Jr, MD, Leslie Silberstein, MD, Helen Heslop, MD and Jeffrey I. Weitz, MD, FACP. Publisher: Elsevier Saunders.